Publications

Year Pmid Doi Title Journal Authors
20254017639210.1002/prp2.70083Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real-World Evidence From an Italian Single-Center Study.Pharmacology research & perspectivesPerrotta N, Fiorito LA, Casini G, Gentile R, Vescovo R, Piciocchi A, Lobello R, Cappelli C, Poscia R, Cimino G
20254008354110.33393/grhta.2025.3365Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL).Global & regional health technology assessmentScortichini M, Paoletti M, Ragonese A, Cuneo A, Vignetti M, Zinzani PL
20254004874210.1182/bloodadvances.2024014901Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML.Blood advancesMarconi G, Piciocchi A, Audisio E, Papayannidis C, Cerrano M, Minotti C, Paoloni F, Guolo F, Bocchia M, Rondoni M, Lico A, Carrabba MG, Della Porta MG, Frigeni M, Giaccone L, Beltrami G, Cattaneo C, Di Chio MC, Serio B, Crea E, Freilone R, Capria S, Curti A, Minetto P, la Sala E, Nanni J, Zannetti BA, Simonetti G, Bochicchio MT, Saglio G, Lemoli RM, Venditti A, Vignetti M, Fazi P, Martinelli G
20254000949010.1182/blood.2024027500Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph- B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study.BloodBassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M, Elia L, Cardinali D, De Propris MS, Piccini M, Lussana F, Annunziata M, Chiusolo P, Zappasodi P, Borlenghi E, Leoncin M, Califano C, Bocchia M, Di Raimondo F, Grimaldi F, Tiribelli M, Candoni A, Lico A, Audisio E, Lunghi M, Mianulli AM, Di Trani M, Arena V, Messina M, Piciocchi A, Fazi P, Rambaldi A, Foà R
20253994902310.2450/BloodTransfus.790Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT.Blood transfusion = Trasfusione del sangueLa Rocca U, Ricci R, Piciocchi A, Barberi W, Oldani E, Dominietto A, Cerretti R, Picardi A, Bonifazi F, Saccardi R, Faraci M, Grillo G, Farina L, Bruno B, Grassi A, Proia A, Tagliaferri E, De Simone G, Malagola M, Cerno M, Cesaro S, Bernasconi P, Prezioso L, Carluccio P, Mordini N, Pelosini M, Olivieri A, Chiusolo P, Santarone S, Cimminiello M, Crocchiolo R, Papola F, Rombolà G, Sacchi N, Miotti V, Mele L, Mazzi B, Ciceri F, Martino M, Iori AP
20253994172610.3390/cancers17030354Long-Term Survival with Multiple Myeloma: An Italian Experience.CancersFazio F, Gherardini M, Rossi E, Za T, Di Landro F, Morè S, Manieri VM, Liberatore C, Chavez MG, Bongarzoni V, Gumenyuk S, Garzia MG, Ruggeri M, Rago A, Biglietto M, Franceschini L, Tomarchio V, De Padua L, Piciocchi A, Mengarelli A, Fiorini A, Fioritoni F, Offidani M, De Stefano V, Martelli M, Petrucci MT
20253991392810.1182/bloodadvances.2024013744FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.Blood advancesVenditti A, Palmieri R, Maurillo L, Röllig C, Wierzbowska A, de Leeuw DC, Efficace F, Curti A, Ngai LL, Tettero JM, Adès L, Almeida AM, Bullinger L, Dennis M, Esteve J, Ferrara F, Heuser M, Huls GA, Lübbert M, Mehta P, Montesinos P, Pabst T, Récher C, Rossi G, Russell NH, Sierra J, Stauder R, Vey N, Walter RB, Wang ES, Nier S, Martins CG, Ossenkoppele GJ
20253983693410.1200/JCO-24-02021Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: An Ethical Imperative.Journal of clinical oncology : official journal of the American Society of Clinical OncologyBlackstone EC, Efficace F, Meyerhardt JA, Abel GA
20253966867110.1097/CMR.0000000000001014Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results.Melanoma researchAl-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM
20253953386810.1111/bjh.19897Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.British journal of haematologyGurnari C, Galossi E, Lumia E, Piciocchi A, Divona M, Casciani E, Romano F, Diral E, Tomelleri A, Caroni F, Vitale A, Bergonzi GM, Condorelli A, Battipaglia G, Morsia E, Crisà E, Triggianese P, Savi A, Cardamone C, Dragani M, Rivoli G, Pilo F, Firinu D, Plebani S, D'Agostino F, D'Ambrosio A, Sockel K, Papayannidis C, Salmoiraghi S, Pane F, Bocchia M, Cantarini L, Frigeni M, Campochiaro C, Dagna L, Greco R, Ciceri F, Spinelli O, Thiede C, Voso MT
20253950448510.1182/blood.2024026186Acute promyelocytic leukemia: long-term outcomes from the HARMONY project.BloodVoso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell N, Dillon R, Thomas I, Ossenkoppele G, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Ramiro AV, Giménez LT, Gurnari C, Bullinger L, Hernández-Rivas JM
20253932254110.1016/j.clml.2024.08.009Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.Clinical lymphoma, myeloma & leukemiaBreccia M, Cucci R, Marsili G, Castagnetti F, Galimberti S, Izzo B, Sorà F, Soverini S, Messina M, Piciocchi A, Bonifacio M, Cilloni D, Iurlo A, Martinelli G, Rosti G, Stagno F, Fazi P, Vignetti M, Pane F
20253915787510.3324/haematol.2024.285638Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.HaematologicaLazzarotto D, Cerrano M, Papayannidis C, Chiaretti S, Mosna F, Fracchiolla N, Zappasodi P, Imbergamo S, Del Principe MI, Lunghi M, Lussana F, Piccini M, Fumagalli M, Dargenio M, Salutari P, Forghieri F, Da Molin TG, Bonifacio M, Olivi M, Giglio F, Trappolini S, Leoncin M, Mule A, Delia M, Pasciolla C, Grimaldi F, Cambo B, Santoro L, Guolo F, Minetto P, Defina M, Chiusolo P, Fanin M, Mauro E, Aprile L, Mazzone C, Trastulli F, Ciccone M, De Gobbi M, Cignetti A, De Bellis E, Mancini V, Piciocchi A, Vignetti M, Marsili G, Starza ID, Fanin R, Luppi M, Ferrara F, Pizzolo G, Bassan R, Foa R, Candoni A
20243969124710.1002/jha2.1045A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real-world practice.EJHaemMessina M, Piciocchi A, Siena LM, Soddu S, Buccisano F, Mecucci C, Martinelli G, Curti A, Cairoli R, Fazi P, Vignetti M, Voso MT, Venditti A, Candoni A
20243964433410.1007/s00277-024-06129-5Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes.Annals of hematologyShah D, Sparano F, Luo C, Krepper D, Giesinger JM, Baldi T, Duncan E, Pe M, Chakraborty R, Efficace F
20243961923910.1016/j.eclinm.2024.102914Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review.EClinicalMedicineOsanto S, Vliert-Bout AV, Gomez de Segura CA, Efficace F, Sparano F, Willemse PP, Schoones J, Cohen A, Barjesteh van Waalwijk van Doorn-Khosrovani S
20243954156010.1200/GO-24-00281Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study.JCO global oncologyTadesse F, Sparano F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M, Krepper D, Gemechu L, Mulu A, Asres G, Efficace F
20243946539210.1007/s00277-024-06047-6Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group.Annals of hematologyForghieri F, Bettelli F, Sgromo S, Nadali G, Del Principe MI, Buzzatti E, Farina F, Cesini L, Giordano A, Criscuolo M, Facchinelli D, Piedimonte M, Sartor C, De Marchi R, Delia M, Mosna F, Cudillo L, Tolomelli G, Basilico CM, Cattaneo C, Fracchiolla NS, Lessi F, Finizio O, Zannetti BA, Santoni A, Fazi P, Marchesi F, Venditti A, Candoni A, Luppi M, Busca A, Pagano L
20243943832210.1007/s00277-024-06038-7Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.Annals of hematologyEfficace F, Sparano F, Breccia M, Greco C, Carluccio P, Borlenghi E, Salutari P, Levato L, Baldi T, Mancini V, Finizio O, Autore F, Fazi P, Platzbecker U, Vignetti M, Voso MT
20243941003810.3390/cancers16193419The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population.CancersUrru SAM, Mayer F, Spila Alegiani S, Paoloni F, Guella A, Murru R, Bucaneve G, Formoso G, Racanelli V, Ferrarini I, Fozza C, Longo G, Musicco F, Campomori A
20243932211810.1016/j.modpat.2024.100615Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncAakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo VK, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Xie Z, Xu ML, Hasserjian RP, Loghavi S
20243927586510.1111/bjh.19759Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.British journal of haematologyCicconi L, Bisegna M, Gurnari C, Fanciullo D, Piciocchi A, Marsili G, Minotti C, Scalzulli E, Mandelli B, Guarnera L, Perrone S, Ortu La Barbera E, Mecarocci S, Biagi A, Cenfra N, Corbingi A, Scerpa MC, Venditti A, Martelli M, Voso MT, Breccia M, Pulsoni A
20243926535410.1016/j.intimp.2024.113101Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience.International immunopharmacologyPerrotta N, Angelo Fiorito L, Leanza C, Di Bari S, Casini G, Gentile R, Vescovo R, Piciocchi A, Ajassa C, Iaiani G, Maria Proli E, Russo G
20243919963510.3390/cancers16162864Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years.CancersCapria S, Trisolini SM, Torrieri L, Amabile E, Marsili G, Piciocchi A, Barberi W, Iori AP, Diverio D, Carmini D, Breccia M, Martelli M, Minotti C
20243914820210.1111/myc.13781Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM).MycosesMarianna C, Matteo B, Alfonso P, Francesca F, Luisa V, Francesco M, Claudia B, Maria Ilaria DP, Maria Chiara T, Chiara C, Marco P, Valentina B, Nicola F, Anna C, Katia P, Marta S, Anna Rita L, Maurizio S, Alessandro B, Livio P,
20243912458810.3390/jcm13154321IPINeT Ped-unPAD Study: Goals, Design, and Preliminary Results.Journal of clinical medicineSgrulletti M, Baselli LA, Castagnoli R, Del Duca E, Graziani S, Moscato GMF, Di Cesare S, Di Matteo G, Cifaldi C, Rossano M, Ballerini C, Piciocchi A, Licari A, Marseglia GL, Consolini R, Moschese V
20243911568810.1007/s00277-024-05927-1Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group.Annals of hematologyForghieri F, Cordella S, Marchesi F, Itri F, Del Principe MI, Cavalieri E, Pasciolla C, Bonanni M, Criscuolo M, Fiorentini A, Guolo F, Buquicchio C, Prezioso L, Delia M, Melillo L, Audisio E, Zannier ME, Cerchione C, Dargenio M, Cattaneo C, Fracchiolla NS, Pezone S, Perruccio K, Santoni A, Candoni A, Vignetti M, Luppi M, Pagano L, Busca A
20243907843610.1007/s00277-024-05914-6Response to Dr. Ying Cui comments.Annals of hematologyMulas O, Efficace F, Costa A, Baldi T, Zerbini F, Mantovani D, Morelli E, Perra D, La Nasa G, Caocci G
20243900234610.1016/j.ejca.2024.114210Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.European journal of cancer (Oxford, England : 1990)Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker LM, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detourmignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H
20243898727410.1038/s41375-024-02341-4Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.LeukemiaEfficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S
20243898409310.4084/MJHID.2024.053Hodgkin Lymphoma in Children: A 16-year Experience at the Children's Welfare Teaching Hospital of Baghdad, Iraq.Mediterranean journal of hematology and infectious diseasesTesti AM, Al-Jadiry MF, Moleti ML, Uccini S, Al-Darraij AF, Al-Saeed RM, Ghali HH, Sabhan AH, Fadhil SA, Al-Badri SA, Alsaadawi AR, Hameedi AD, Shanshal MH, Al-Agele YS, Al-Saffar FAR, Yaseen NK, Piciocchi A, Marsili G, Al-Hadad SA
20243897954910.33393/grhta.2024.3042Exploring the administrative burden faced by hematologists: a comprehensive study in Italy.Global & regional health technology assessmentPetruzzelli D, Vignetti M, Trasarti S, Sportoletti P, Torre SD, Cairoli R, Leone FPC, Pompilio G, Gullì M, Hajdukova EB, Integlia D
20243896813910.1182/bloodadvances.2024013182Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.Blood advancesVenditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Filì C, Carella AM, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Curti A, Luppi M, Ingrosso C, Martelli MP, Cuneo A, Albano F, Mulè A, Tafuri A, Cudillo L, Tieghi A, Fracchiolla NS, Capelli D, Trisolini SM, Alati C, La Sala E, Maurillo L, Del Principe MI, Irno Consalvo MA, Divona MD, Ottone T, Cerretti R, Sconocchia G, Voso MT, Fazi P, Vignetti M, Buccisano F
20243889506910.1002/jha2.907Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.EJHaemFazio F, Petrucci MT, Corvatta L, Piciocchi A, Della Pepa R, Tacchetti P, Musso M, Zambello R, Belotti A, Bringhen S, Antonioli E, Conticello C, Renzo ND, De Stefano V, Musto P, Gamberi B, Derudas D, Boccadoro M, Offidani M, Morè S
20243888245910.4084/MJHID.2024.041Impact of Daratumumab on Stem Cell Mobilization and Transplant in Patient with Newly Diagnosed Multiple Myeloma: A Real Word Single-Centre Study.Mediterranean journal of hematology and infectious diseasesPassucci M, Fazio F, Micozzi J, Bafti MS, Assanto G, Piciocchi A, Martelli M, Petrucci MT
20243877465510.1002/hem3.69Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).HemaSphereEfficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, Stahl M, Platzbecker U, Sekeres MA, Zeidan AM
20243874444710.1136/spcare-2024-004842Early palliative care perceptions by patients with cancer and primary caregivers: metaphorical language.BMJ supportive & palliative careBandieri E, Bigi S, Nava M, Borelli E, Porro CA, Castellucci E, Efficace F, Bruera E, Odejide O, Zimmermann C, Potenza L, Luppi M
20243872422210.1136/spcare-2024-004924Financial toxicity and health-related quality of life in long-term survivors of acute promyelocytic leukaemia.BMJ supportive & palliative careSparano F, Voso MT, Venditti A, Giesinger JM, Baldi T, Breccia M, Fazi P, Vignetti M, Efficace F
20243871786110.1182/blood.2023023625Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.BloodEfficace F, Kicinski M, Coens C, Suciu S, van der Velden WJFM, Noppeney R, Chantepie S, Griskevicius L, Neubauer A, Audisio E, Luppi M, Fuhrmann S, Foà R, Crysandt M, Gaidano G, Vrhovac R, Venditti A, Posthuma EFM, Candoni A, Baron F, Legrand O, Mengarelli A, Fazi P, Vignetti M, Giraut A, Wijermans PW, Huls G, Lübbert M
20243867129810.1007/s00277-024-05771-3Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura.Annals of hematologyMulas O, Efficace F, Costa A, Baldi T, Zerbini F, Mantovani D, Morelli E, Perra D, La Nasa G, Caocci G
20243863311510.1002/jha2.873Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients.EJHaemPiciocchi A, Cipriani M, Messina M, Marconi G, Arena V, Soddu S, Crea E, Feraco MV, Ferrante M, La Sala E, Fazi P, Buccisano F, Voso MT, Martinelli G, Venditti A, Vignetti M
20243860660510.7189/jogh-14-04068Key lifestyles and health outcomes across 16 prevalent chronic diseases: A network analysis of an international observational study.Journal of global healthLi J, Fong DYT, Lok KYW, Wong JYH, Man Ho M, Choi EPH, Pandian V, Davidson PM, Duan W, Tarrant M, Lee JJ, Lin CC, Akingbade O, Alabdulwahhab KM, Ahmad MS, Alboraie M, Alzahrani MA, Bilimale AS, Boonpatcharanon S, Byiringiro S, Hasan MKC, Schettini LC, Corzo W, De Leon JM, De Leon AS, Deek H, Efficace F, El Nayal MA, El-Raey F, Ensaldo-Carrasco E, Escotorin P, Fadodun OA, Fawole IO, Goh YS, Irawan D, Khan NE, Koirala B, Krishna A, Kwok C, Le TT, Leal DG, Lezana-Fernández MÁ, Manirambona E, Mantoani LC, Meneses-González F, Mohamed IE, Mukeshimana M, Nguyen CTM, Nguyen HTT, Nguyen KT, Nguyen ST, Nurumal MS, Nzabonimana A, Omer NAMA, Ogungbe O, Poon ACY, Reséndiz-Rodriguez A, Puang-Ngern B, Sagun CG, Shaik RA, Shankar NG, Sommer K, Toro E, Tran HTH, Urgel EL, Uwiringiyimana E, Vanichbuncha T, Youssef N
20243858222710.1016/j.critrevonc.2024.104345Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review.Critical reviews in oncology/hematologyRoets E, van der Graaf W, van Riet BHG, Haas RL, Younger E, Sparano F, Wilson R, van der Mierden S, Steeghs N, Efficace F, Husson O
20243847802310.1007/s00277-024-05704-0Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.Annals of hematologyPalandri F, Auteri G, Abruzzese E, Caocci G, Bonifacio M, Mendicino F, Latagliata R, Iurlo A, Branzanti F, Garibaldi B, Trawinska MM, Cattaneo D, Krampera M, Mulas O, Martino EA, Cavo M, Vianelli N, Impera S, Efficace F, Heidel F, Breccia M, Elli EM, Palumbo GA
20243846129210.1038/s41409-024-02260-zEffect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.Bone marrow transplantationFazio F, Passucci M, Micozzi J, Di Landro F, Fianchi L, Za T, Manieri VM, Annibali O, Cupelli L, Bongarzoni V, Gentili S, De Padua L, Crisanti E, Garzia MG, Rago A, Piciocchi A, Mengarelli A, Morè S, De Stefano V, Bafti MS, Martelli M, Petrucci MT
20243842421410.1038/s41591-024-02827-9Recommendations to address respondent burden associated with patient-reported outcome assessment.Nature medicineAiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV, Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson R, Calvert MJ
20243820723910.1200/OP.23.00434Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System.JCO oncology practiceSparano F, Giesinger JM, Gaidano G, Anota A, Cavo M, Brini A, Voso MT, Venditti A, Perrone F, Di Maio M, Luppi M, Baron F, Platzbecker U, Fazi P, Vignetti M, Efficace F
20243817497710.1002/ajh.27196Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.American journal of hematologyBaron F, Efficace F, Cannella L, Stevens-Kroef M, Amadori S, de Witte T, Lübbert M, Venditti A, Suciu S
20243812772210.1200/JCO.23.01075Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.Journal of clinical oncology : official journal of the American Society of Clinical OncologyFoà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, Ferrara F, Lunghi M, Mulè A, Bonifacio M, Fracchiolla N, Salutari P, Fazi P, Guarini A, Rambaldi A, Chiaretti S
20243811346710.1182/bloodadvances.2023011661A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.Blood advancesEnshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, Moorman AV
20243784721110.2450/BloodTransfus.464Donor specific anti-HLA antibodies in hematopoietic stem cell transplantation. Single Center prospective evaluation and desensitization strategies employed.Blood transfusion = Trasfusione del sangueLa Rocca U, Perrone MP, Piciocchi A, Barberi W, Gesuiti P, Laurenti L, Cinti P, Gozzer M, Bafti MS, Carmini D, Cinelli N, Cavallari C, Giovannetti G, Ricci R, Girelli G, Foà R, Martelli M, Coluzzi S, Iori AP
20243780105210.1002/cncr.35021Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.CancerEfficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, Patriarca A, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Giai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D
20243775199510.1136/spcare-2023-004524Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study.BMJ supportive & palliative careGiusti D, Colaci E, Pioli V, Banchelli F, Maccaferri M, Leonardi G, Marasca R, Morselli M, Forghieri F, Bettelli F, Cuoghi A, Bresciani P, Messerotti A, Gilioli A, Candoni A, Cassanelli L, Sbadili E, Bassoli I, Longo G, Gilioli F, Borelli E, Bigi S, D'Amico R, Porro CA, Odejide O, Zimmermann C, Efficace F, Bruera E, Luppi M, Bandieri E, Potenza L
20243740851510.1177/11297298231185222Peripherally inserted central venous catheter for pediatric acute leukemia: A retrospective 11-year single-center experience.The journal of vascular accessLigia S, Morano SG, Kaiser F, Micozzi A, Chistolini A, Barberi W, Arena V, Piciocchi A, Forgione M, Gasperini G, Berneschi P, Testi AM
20243561841210.1136/bmjspcare-2022-003572Edmonton symptom assessment system global distress score and overall survival among patients with advanced cancer receiving early palliative care.BMJ supportive & palliative careBandieri E, Banchelli F, Borelli E, D'Amico R, Efficace F, Bruera E, Luppi M, Potenza L
20233805210410.1016/j.esmoop.2023.102192Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients.ESMO openArenare L, Porta C, Barberio D, Terzolo S, Zagonel V, Pisconti S, Del Mastro L, Pinto C, Bilancia D, Cinieri S, Rizzo M, Migliaccio G, Montesarchio V, Del Campo L, De Lorenzo F, Iannelli E, Traclò F, Gitto L, Vaccaro MC, Frontini L, Giannarelli D, Bryce J, Piccirillo MC, Jommi C, Efficace F, Riva S, Di Maio M, Gallo C, Perrone F
20233791448210.1016/S2352-3026(23)00273-910-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.The Lancet. HaematologyLübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G,
20233786113010.7189/jogh.13.04125Key lifestyles and interim health outcomes for effective interventions in general populations: A network analysis of a large international observational study.Journal of global healthLi J, Fong DYT, Lok KYW, Wong JYH, Ho MM, Choi EPH, Pandian V, Davidson PM, Duan W, Tarrant M, Lee JJ, Lin CC, Akingbade O, Alabdulwahhab KM, Ahmad MS, Alboraie M, Alzahrani MA, Bilimale AS, Boonpatcharanon S, Byiringiro S, Hasan MKC, Schettini LC, Corzo W, De Leon JM, De Leon AS, Deek H, Efficace F, El Nayal MA, El-Raey F, Ensaldo-Carrasco E, Escotorin P, Fadodun OA, Fawole IO, Goh YS, Irawan D, Khan NE, Koirala B, Krishna A, Kwok C, Le TT, Leal DG, Lezana-Fernández MÁ, Manirambona E, Mantoani LC, Meneses-González F, Mohamed IE, Mukeshimana M, Nguyen CTM, Nguyen HTT, Nguyen KT, Nguyen ST, Nurumal MS, Nzabonimana A, Omer NAMA, Ogungbe O, Poon ACY, Reséndiz-Rodriguez A, Puang-Ngern B, Sagun CG, Shaik RA, Shankar NG, Sommer K, Toro E, Tran HTH, Urgel EL, Uwiringiyimana E, Vanichbuncha T, Youssef N
20233778119210.3389/fonc.2023.1213906Caregiver's quality of life in advanced cancer: validation of the construct in a real-life setting of early palliative care.Frontiers in oncologyBorelli E, Bigi S, Potenza L, Gilioli F, Efficace F, Porro CA, Luppi M, Bandieri E
20233777326510.1038/s41375-023-02046-0Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform.LeukemiaEnshaei A, Martinez Elicegui J, Anguiano E, Gibson J, Lawal S, Ampatzidou M, Doubek M, Fielding AK, La Sala E, Middleton E, Rijneveld AW, Turki AT, Zimmermann M, Vora A, Moorman AV
20233776298710.3390/jcm12186047Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation.Journal of clinical medicineMulas O, Efficace F, Orofino MG, Piroddi A, Piras E, Vacca A, Barella S, Costa A, Giesinger JM, La Nasa G, Caocci G
20233770552510.4084/MJHID.2023.047Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience.Mediterranean journal of hematology and infectious diseasesFazio F, Lapietra G, Limongi MZ, Intoppa S, Milani ML, Piciocchi A, Martelli M, Guarini A, Foà R, De Propris MS, Petrucci MT
20233770446910.1016/j.blre.2023.101128Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).Blood reviewsStahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM
20233769311810.1177/20406207231190683Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy.Therapeutic advances in hematologyDe Muro M, Janssen AJ, Amadori S, de Fabritiis P, Sabatino D, Niscola P, Torti L, Trawinska MM, Tesei C, Bombaci F, Tarricone M, Bocchia M, Fava C, Galimberti S, Iurlo A, Luciano L, Abruzzese E
20233766367110.1097/HS9.0000000000000944Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA.HemaSphereEfficace F, Al Essa W, Platzbecker U, Niscola P, Palumbo GA, Caocci G, Cottone F, Breccia M, Luppi M, Stauder R, Ricco A, Petranovic D, Baron F, Voso MT, Fianchi L, Frairia C, Capodanno I, Sarlo C, Fedele M, Lemoli RM, Invernizzi R, Vallisa D, Di Renzo N, Fozza C, Doro M, Giesinger JM, Vignetti M
20233763470210.1016/j.jclinepi.2023.08.009The estimand framework had implications in time to patient-reported outcomes deterioration analyses in cancer clinical trials.Journal of clinical epidemiologyCottone F, Efficace F, Cella D, Aaronson NK, Giesinger JM, Bachet JB, Louvet C, Charton E, Collins GS, Anota A
20233762930810.3390/jcm12165267Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey.Journal of clinical medicineBreccia M, Piciocchi A, Abruzzese E, Cilloni D, Messina M, Soddu S, Castagnetti F, Stagno F, Fazi P, Iurlo A, Caocci G, Gozzini A, Intermesoli T, D'Adda M, Pane F
20233756539410.7189/jogh.13.06031Global impacts of COVID-19 on lifestyles and health and preparation preferences: An international survey of 30 countries.Journal of global healthLi J, Fong DYT, Lok KYW, Wong JYH, Man Ho M, Choi EPH, Pandian V, Davidson PM, Duan W, Tarrant M, Lee JJ, Lin CC, Akingbade O, Alabdulwahhab KM, Ahmad MS, Alboraie M, Alzahrani MA, Bilimale AS, Boonpatcharanon S, Byiringiro S, Hasan MKC, Schettini LC, Corzo W, De Leon JM, De Leon AS, Deek H, Efficace F, El Nayal MA, El-Raey F, Ensaldo-Carrasco E, Escotorin P, Fadodun OA, Fawole IO, Goh YS, Irawan D, Khan NE, Koirala B, Krishna A, Kwok C, Le TT, Leal DG, Lezana-Fernández MÁ, Manirambona E, Mantoani LC, Meneses-González F, Mohamed IE, Mukeshimana M, Nguyen CTM, Nguyen HTT, Nguyen KT, Nguyen ST, Nurumal MS, Nzabonimana A, Omer NAMA, Ogungbe O, Poon ACY, Reséndiz-Rodriguez A, Puang-Ngern B, Sagun CG, Shaik RA, Shankar NG, Sommer K, Toro E, Tran HTH, Urgel EL, Uwiringiyimana E, Vanichbuncha T, Youssef N
20233751750410.1016/j.jclinepi.2023.07.012Information about missing patient-reported outcome data in breast cancer trials is frequently not documented: a scoping review.Journal of clinical epidemiologyKrepper D, Giesinger JM, Dirven L, Efficace F, Martini C, Thurner AMM, Al-Naesan I, Gross F, Sztankay MJ
20233750931710.3390/cancers15143656Stigma of Palliative Care among Patients with Advanced Cancer and Their Caregivers on Early Palliative Care.CancersBandieri E, Borelli E, Gilioli F, Bigi S, Mucciarini C, Ferrari U, Eliardo S, Pinto L, Porro CA, Efficace F, Luppi M, Potenza L
20233745278910.1080/10428194.2023.2235450Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.Leukemia & lymphomaCardinali D, Beldinanzi M, Ansuinelli M, Elia L, Della Starza I, Bellomarino V, Matarazzo M, Di Trani M, Cola M, Salutari P, Cedrone M, Bassan R, De Gobbi M, Della Porta MG, De Simone M, Alati C, Fracchiolla NS, Lunghi M, Intermesoli T, Cardinali V, Mulè A, Guarini A, Foà R, Chiaretti S
20233739214110.1002/hon.3199Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.Hematological oncologyAutore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA, Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR, Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R, Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A, Laurenti L
20233732711610.1182/bloodadvances.2023010173Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting.Blood advancesAttardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, Fabiani E, Divona M, Travaglini S, Pascale MR, Awada H, Durmaz A, Visconte V, Della Porta MG, Venditti A, Maciejewski JP, Gurnari C, Voso MT
20233727645110.1182/bloodadvances.2022009596Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.Blood advancesBassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propris MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, Bonifacio M, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R
20233720855610.1007/s12325-023-02497-yPonatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.Advances in therapyRibera JM, Prawitz T, Freitag A, Sharma A, Dobi B, Rizzo F, Sabatelli L, Patos P
20233704863010.3390/jcm12072547Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy.Journal of clinical medicineCaocci G, Mulas O, Barella S, Orecchia V, Mola B, Costa A, Efficace F, La Nasa G
20233699845710.3389/fonc.2023.1152467Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?Frontiers in oncologyAssanto GM, Del Giudice I, Della Starza I, Soscia R, Cavalli M, Cola M, Bellomarino V, Di Trani M, Guarini A, Foà R
20233686421010.1007/s00277-023-05149-xThe prognostic value of patient-reported outcomes in allogeneic hematopoietic stem cell transplantation: exploratory analysis of a randomized nutrition intervention trial.Annals of hematologyGudmundstuen AM, Efficace F, Tjønnfjord GE, Skaarud KJ, Cottone F, Hjermstad MJ, Iversen PO
20233679971510.1111/bjh.18615Correction to "Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study".British journal of haematology
20233672445310.1182/blood.2022018604Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.BloodZeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P
20233667232510.3390/cancers15020374Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia.CancersDella Starza I, De Novi LA, Elia L, Bellomarino V, Beldinanzi M, Soscia R, Cardinali D, Chiaretti S, Guarini A, Foà R
20233665178010.2217/fon-2022-0512ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.Future oncology (London, England)Mannelli F, Guglielmelli P, Fazi P, Crea E, Piciocchi A, Vignetti M, Amadori S, Pane F, Venditti A, Vannucchi AM
20233663273810.3324/haematol.2022.282116High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.HaematologicaMauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R
20233660783210.1182/bloodadvances.2022008360Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood advancesStojkov I, Conrads-Frank A, Rochau U, Arvandi M, Koinig KA, Schomaker M, Mittelman M, Fenaux P, Bowen D, Sanz GF, Malcovati L, Langemeijer S, Germing U, Madry K, Guerci-Bresler A, Culligan DJ, Kotsianidis I, Sanhes L, Mills J, Puntscher S, Schmid D, van Marrewijk C, Smith A, Efficace F, de Witte T, Stauder R, Siebert U
20233654642610.3324/haematol.2022.282268Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study.HaematologicaBenintende G, Innocenti I, Fresa A, Autore F, Tomasso A, Piciocchi A, Vuono F, Stirparo L, Mosca A, Bacigalupo A, Gattei V, Efremov D, Sangiorgi E, Laurenti L
20233653358910.1080/10428194.2022.2148217ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.Leukemia & lymphomaChiaretti S, Taherinasab A, Della Starza I, Canichella M, Ansuinelli M, De Propris MS, Messina M, Spinelli O, Santoro A, De Novi LA, Cardinali D, Schipani M, Arena V, Bassan R, Guarini A, Foà R
20233653341510.1002/cam4.5487Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project.Cancer medicineEfficace F, Koinig K, Cottone F, Bowen D, Mittelman M, Sommer K, Langemeijer S, Culligan D, Filanovsky K, Storck M, Smith A, van Marrewijk C, Dugas M, Stojkov I, Siebert U, de Witte T, Stauder R
20233632012810.1093/oncolo/oyac227Perceptions of Death Among Patients with Advanced Cancer Receiving Early Palliative Care and Their Caregivers: Results from a Mixed-Method Analysis.The oncologistBigi S, Ganfi V, Borelli E, Potenza L, Artioli F, Eliardo S, Mucciarini C, Cottafavi L, Ferrari U, Lombardo L, Cagossi K, Pietramaggiori A, Fantuzzi V, Bernardini I, Cruciani M, Cacciari C, Odejide O, Adolfo Porro C, Zimmermann C, Efficace F, Bruera E, Luppi M, Bandieri E
20233626359310.1111/bjh.18510Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.British journal of haematologyPereira-Martins DA, Coelho-Silva JL, Weinhäuser I, Franca-Neto PL, Silveira DR, Ortiz C, Moreira-Aguiar A, Lima MM, Koury LC, de Melo RA, Glória AB, Fagundes EM, Lino BK, Pagnano K, Bittencourt R, Nunes E, Traina F, Figueiredo-Pontes L, Keating A, Tallman MS, Ribeiro RC, Dilon R, Ganser A, Sanz MA, Berliner N, Valk P, Löwenberg B, Ottone T, Noguera NI, Voso MT, Paoloni F, Fazi P, Ammatuna E, Huls G, Schuringa JJ, Rego EM, Lucena-Araujo AR
20233626070210.1182/bloodadvances.2022008747An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.Blood advancesStahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM
20233625144010.1002/hon.3087Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.Hematological oncologySoscia R, Della Starza I, De Novi LA, Ilari C, Ansuinelli M, Cavalli M, Bellomarino V, Cafforio L, Di Trani M, Cazzaniga G, Fazio G, Santoro A, Salemi D, Spinelli O, Tosi M, Terragna C, Robustelli V, Bellissimo T, Colafigli G, Breccia M, Chiaretti S, Di Rocco A, Martelli M, Guarini A, Del Giudice I, Foà R
20233566143610.1002/cam4.4892Comprehensive global collaboration in the care of 1182 pediatric oncology patients over 12 years: The Iraqi-Italian experience.Cancer medicineAl-Jadiry MF, Uccini S, Testi AM, Moleti ML, Alsaadawi AR, Al-Darraji AF, Al-Saeed RM, Faraj Al-Badri SA, Sabhan AH, Ghali HH, Fadhil SA, Abed WM, Ameen NA, Abed YS, Yousif FS, Abed AR, Hussein HM, Shkara AM, Piciocchi A, Mohamed S, Ruco L, Qaddoumi I, Al-Hadad SA
20233394157310.1136/bmjspcare-2020-002312Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors.BMJ supportive & palliative careOswald LB, Venditti A, Cella D, Cottone F, Candoni A, Melillo L, Cairoli R, Storti G, Salutari P, Luppi M, Albano F, Martelli MP, Cuneo A, Tafuri A, Trisolini SM, Tieghi A, Fazi P, Vignetti M, Efficace F
20223650454710.1097/HS9.0000000000000802Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review.HemaSphereEfficace F, Cannella L, Sparano F, Giesinger JM, Vignetti M, Baron F, Bruera E, Luppi M, Platzbecker U
20223635352910.3389/fonc.2022.991250Gratitude among advanced cancer patients and their caregivers: The role of early palliative care.Frontiers in oncologyBorelli E, Bigi S, Potenza L, Gilioli F, Artioli F, Porzio G, Porro CA, Efficace F, Bruera E, Luppi M, Bandieri E
20223626632610.1038/s41375-022-01724-9Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.LeukemiaZeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V
20223610277710.1016/S2666-7568(22)00172-6Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.The lancet. Healthy longevityEfficace F, Gaidano G, Petrucci MT, Niscola P, Cottone F, Codeluppi K, Antonioli E, Tafuri A, Larocca A, Potenza L, Fozza C, Pastore D, Rigolin GM, Offidani M, Romano A, Kyriakou C, Cascavilla N, Gozzetti A, Derudas D, Vignetti M, Cavo M
20223607104810.1038/s41408-022-00724-3Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.Blood cancer journalGurnari C, Piciocchi A, Soddu S, Bonanni F, Scalzulli E, Niscola P, Di Veroli A, Piccioni AL, Piedimonte M, Maiorana G, Salutari P, Cicconi L, Santopietro M, Gumenyuk S, Sarlo C, Fenu S, Tafuri A, Latagliata R, Fianchi L, Criscuolo M, Maciejewski JP, Maurillo L, Buccisano F, Breccia M, Voso MT
20223596394010.1038/s41375-022-01675-1Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine.LeukemiaBreccia M, Piciocchi A, Messina M, Soddu S, De Stefano V, Bellini M, Iurlo A, Martino B, Siragusa S, Albano F, Mora B, Fazi P, Vignetti M, Guglielmelli P, Palandri F
20223591339610.1080/10428194.2022.2105328Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation.Leukemia & lymphomaTesti AM, Al-Jadiry MF, Ghali HH, Fadhil SA, Al-Darraji AF, Al-Saeed RM, Sabhan AH, Al-Badri SAF, Abed WM, Ameen NA, Al-Tameemi RZ, Al-Assaf AI, Moleti ML, Arena V, Piciocchi A, Foà R, Al-Hadad SA
20223590688110.1111/bjh.18385Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study.British journal of haematologyMarasco V, Piciocchi A, Candoni A, Pagano L, Guidetti A, Musto P, Bruna R, Bocchia M, Visentin A, Turrini M, Tucci A, Pilerci S, Fianchi L, Salvini M, Galimberti S, Coviello E, Selleri C, Luppi M, Crea E, Fazi P, Passamonti F, Corradini P
20223585385010.1038/s41408-022-00702-9Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.Blood cancer journalPagano L, Criscuolo M, Broccoli A, Piciocchi A, Varettoni M, Galli E, Anastasia A, Cantonetti M, Trentin L, Kovalchuk S, Orsucci L, Frustaci A, Spolzino A, Volpetti S, Annibali O, Storti S, Stelitano C, Marchesi F, Offidani M, Casadei B, Nizzoli ME, De Luca ML, Fianchi L, Motta M, Guarnera L, Simonetti E, Visentin A, Vassallo F, Deodato M, Sarlo C, Olivieri A, Falini B, Pulsoni A, Tiacci E, Zinzani PL
20223584621110.1002/jha2.359Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.EJHaemFazio F, Franceschini L, Tomarchio V, Rago A, Garzia MG, Cupelli L, Bongarzoni V, Andriani A, Gumenyuk S, Tafuri A, Siniscalchi A, Piciocchi A, De Fabritiis P, De Rosa L, Caravita di Toritto T, Annibali O, Cantonetti M, Petrucci MT
20223578937510.1182/bloodadvances.2022006964Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.Blood advancesFresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L
20223574067710.3390/cancers14123012Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol.CancersMessina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, Fracchiolla NS, Forghieri F, Candoni A, Mengarelli A, Martelli MP, Venditti A, Carella AM, Albano F, Mancini V, Massimo B, Arena V, Sargentini V, Sciumè M, Pastore D, Todisco E, Roti G, Siragusa S, Ladetto M, Pravato S, De Bellis E, Simonetti G, Marconi G, Cerchione C, Fazi P, Vignetti M, Amadori S, Martinelli G, Voso MT
20223571002710.1016/j.jmoldx.2022.04.014Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia.The Journal of molecular diagnostics : JMDDella Starza I, De Novi LA, Santoro A, Salemi D, Spinelli O, Tosi M, Soscia R, Paoloni F, Cappelli LV, Cavalli M, Apicella V, Bellomarino V, Di Lello E, Vitale A, Vignetti M, Fabbiano F, Rambaldi A, Bassan R, Guarini A, Chiaretti S, Foà R
20223564120710.1093/oncolo/oyab027Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis.The oncologistBigi S, Ganfi V, Borelli E, Potenza L, Artioli F, Eliardo S, Mucciarini C, Cottafavi L, Cruciani M, Cacciari C, Odejide O, Porro CA, Zimmermann C, Efficace F, Bruera E, Luppi M, Bandieri E
20223562232110.1007/978-1-0716-2115-8_5Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR.Methods in molecular biology (Clifton, N.J.)Starza ID, Eckert C, Drandi D, Cazzaniga G,
20223561702510.1111/ejh.13804Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case-control study.European journal of haematologyRago A, Annibali O, Tomarchio V, Coppetelli U, Fazio F, Cupelli L, Fiorini A, Piciocchi A, Tafuri A, Caravita di Toritto T
20223561061110.1186/s12889-022-13211-yEORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.BMC public healthPilz MJ, Gamper EM, Efficace F, Arraras JI, Nolte S, Liegl G, Rose M, Giesinger JM,
20223538592210.3324/haematol.2021.280175Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.HaematologicaGugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sorà F, Simula MP, Albano F, Soverini S, Foà R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G
20223537207910.3389/fonc.2022.826040Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform.Frontiers in oncologyEfficace F, Patriarca A, Luppi M, Potenza L, Caocci G, Tafuri A, Fazio F, Cartoni C, Petrucci MT, Carmosino I, Moia R, Margiotta Casaluci G, Boggione P, Colaci E, Giusti D, Pioli V, Sparano F, Cottone F, De Fabritiis P, Ardu NR, Niscola P, Capodanno I, Leporace AP, Pelliccia S, Lugli E, La Sala E, Rigacci L, Santopietro M, Fozza C, Siragusa S, Breccia M, Fazi P, Vignetti M
20223532293210.1002/cam4.4692Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.Cancer medicineHuang H, Datye A, Fan M, Knapp A, Nielsen T, Bottos A, Paulson JN, Trask PC, Efficace F
20223531512810.1002/ajh.26537Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.American journal of hematologyTorelli GF, Chiaretti S, Peragine N, Barberi W, Santodonato L, D'Agostino G, Abruzzese E, Del Principe MI, Mancino A, Matarazzo M, Bafti MS, Mancini M, Messina M, Castiello L, Guarini A, Foà R
20223529507610.3324/haematol.2021.279777Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.HaematologicaBuccisano F, Palmieri R, Piciocchi A, Arena V, Maurillo L, Del Principe MI, Paterno G, Irno-Consalvo MA, Ottone T, Divona M, Conti C, Fraboni D, Lavorgna S, Arcese W, Voso MT, Venditti A
20223525515210.1111/bjh.18072International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.British journal of haematologyOerlemans S, Efficace F, Kieffer JM, Kyriakou C, Xochelli A, Levedahl K, Petranovic D, Borges FC, Bredart A, Shamieh O, Gziskevicius L, Lehmann J, Scholz CW, Caocci G, Molica S, Stamatopoulos K, Panteliadou AK, Papaioannou M, Alrjoob W, Baliakas P, Rosenquist R, Malak S, Miranda A, Cocks K, van de Poll-Franse L,
20223519950510.3324/haematol.2021.280325Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.HaematologicaInnocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, Moia R, Gentile M, Pennese E, Quaglia FM, Albano F, Cassin R, Deodato M, Ielo C, Frustaci AM, Piciocchi A, Rughini A, Arena V, Di Sevo D, Tomasso A, Autore F, Del Poeta G, Scarfò L, Mauro FR, Tedeschi A, Trentin L, Pompili M, Foà R, Ghia P, Cuneo A, Laurenti L
20223518347610.1016/j.clml.2022.01.009Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021.Clinical lymphoma, myeloma & leukemiaEfficace F, Cottone F, Sparano F, Caocci G, Vignetti M, Chakraborty R
20223515874610.3390/cancers14030478Early Palliative Care in Acute Myeloid Leukemia.CancersPotenza L, Borelli E, Bigi S, Giusti D, Longo G, Odejide O, Porro CA, Zimmermann C, Efficace F, Bruera E, Luppi M, Bandieri E
20223513322710.1080/10428194.2022.2032035Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.Leukemia & lymphomaFazio F, Cunsolo G, Mancini F, De Propris MS, Piciocchi A, Arena V, Messina M, Ansuinelli M, Taherinasab AT, Apicella V, Vitale A, Chiaretti S, Guarini A, Del Giudice I, Foà R
20223509836610.1007/s00277-021-04750-2Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy.Annals of hematologyCaocci G, Efficace F, Mulas O, Cottone F, Maxia A, Costa A, Simula MP, Usala E, La Nasa G
20223480652510.1080/10428194.2021.2005042CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.Leukemia & lymphomaPalmieri R, Buccisano F, Arena V, Irno Consalvo MA, Piciocchi A, Maurillo L, DelPrincipe MI, Di Veroli A, Paterno G, Conti C, Fraboni D, Voso MT, Arcese W, Venditti A
20223473188410.1182/bloodadvances.2021005717ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol.Blood advancesBuccisano F, Palmieri R, Piciocchi A, Arena V, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Capria S, Maurillo L, Del Principe MI, Paterno G, Irno Consalvo MA, Ottone T, Lavorgna S, Voso MT, Fazi P, Vignetti M, Arcese W, Venditti A
20223464927610.1182/bloodadvances.2021004821INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.Blood advancesMartinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RM, Guolo F, Fornaro A, Lunghi M, de Fabritiis P, Candoni A, Selleri C, Simonetti F, Bocchia M, Vitale A, Frison L, Tedeschi A, Cuneo A, Bonifacio M, Martelli MP, D'Ardia S, Trappolini S, Tosi P, Galieni P, Fabbiano F, Abbenante MC, Granier M, Zhu Z, Wang M, Sartor C, Paolini S, Cavo M, Foà R, Fazi P, Vignetti M, Baccarani M
20223464743910.3324/haematol.2020.263715Treatment with ibrutinib does not induce a clonal evolution in chronic lymphocytic leukemia.HaematologicaCafforio L, Raponi S, Cappelli LV, Ilari C, Soscia R, De Propris MS, Mariglia P, Rigolin GM, Bardi A, Peragine N, Piciocchi A, Arena V, Mauro FR, Cuneo A, Guarini A, Foa R, Del Giudice I
20223452160910.1016/j.jgo.2021.09.007Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia.Journal of geriatric oncologyPeipert JD, Efficace F, Pierson R, Loefgren C, Cella D, He J
20223450861010.1093/jnci/djab177Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials.Journal of the National Cancer InstituteEfficace F, Cella D, Aaronson NK, Calvert M, Cottone F, Di Maio M, Perrone F, Sparano F, Gamper EM, Vignetti M, Giesinger JM
20223449268410.1182/bloodadvances.2021004568Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists.Blood advancesStojkov I, Conrads-Frank A, Rochau U, Koinig KA, Arvandi M, Puntscher S, van Marrewijk C, Fenaux P, Symeonidis A, Chermat F, Garelius H, Bowen D, Mittelman M, Mora E, de Witte T, Efficace F, Siebert U, Stauder R
20223449136410.1093/jnci/djab185Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most?Journal of the National Cancer InstituteEfficace F, Baccarani M
20223268089510.1136/bmjspcare-2020-002281Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden.BMJ supportive & palliative careSommer K, Vignetti M, Cottone F, Breccia M, Annibali O, Luppi M, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Romani C, Sborgia M, Martino B, Crugnola M, Efficace F
20213544470810.2174/1745017902117010307Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.Clinical practice and epidemiology in mental health : CP & EMHGiesinger JM, La Nasa G, Sparano F, Angermeyer M, Morelli E, Mulas O, Efficace F, Caocci G
20213500837210.3390/cancers14010207Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.CancersMauro FR, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, Marchetti M, Pietrasanta D, Marasca R, Gaidano G, Coscia M, Stelitano C, Mannina D, Di Renzo N, Ilariucci F, Liberati AM, Orsucci L, Re F, Tani M, Musuraca G, Gottardi D, Zinzani PL, Gozzetti A, Molinari A, Gentile M, Chiarenza A, Laurenti L, Varettoni M, Ibatici A, Murru R, Ruocco V, Del Giudice I, De Propris MS, Della Starza I, Raponi S, Nanni M, Fazi P, Neri A, Guarini A, Rigolin GM, Piciocchi A, Cuneo A, Foà R
20213483826810.1016/j.jval.2021.06.003Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchEfficace F, Giesinger JM, Cella D, Cottone F, Sparano F, Vignetti M, Aaronson NK
20213475014510.1136/bmjspcare-2021-002898Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study.BMJ supportive & palliative carePotenza L, Scaravaglio M, Fortuna D, Giusti D, Colaci E, Pioli V, Morselli M, Forghieri F, Bettelli F, Messerotti A, Catellani H, Gilioli A, Marasca R, Borelli E, Bigi S, Longo G, Banchelli F, D'Amico R, L Back A, Efficace F, Bruera E, Luppi M, Bandieri E
20213467076210.1136/bmjopen-2021-049128Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system.BMJ openRiva S, Arenare L, Di Maio M, Efficace F, Montesarchio V, Frontini L, Giannarelli D, Bryce J, Del Campo L, De Lorenzo F, Iannelli E, Traclò F, Gitto L, Jommi C, Vaccaro CM, Barberio D, Cinieri S, Porta C, Del Mastro L, Zagonel V, Cogoni AA, Bordonaro R, Gimigliano A, Piccirillo MC, Guizzaro L, Gallo C, Perrone F
20213466182610.1007/s11523-021-00831-4Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.Targeted oncologyCastagnetti F, Binotto G, Capodanno I, Billio A, Calistri E, Cavazzini F, Crugnola M, Gozzini A, Gugliotta G, Krampera M, Lucchesi A, Merli A, Miggiano MC, Minotto C, Poggiaspalla M, Salvucci M, Scappini B, Tiribelli M, Trabacchi E, Rosti G, Galimberti S, Bonifacio M
20213464437610.1182/bloodadvances.2021005802Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey.Blood advancesValentini CG, Piciocchi A, Facchetti F, Guolo F, Pulsoni A, Vignetti M, Pagano L
20213458723310.1182/blood.2021011883Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.BloodRigolin GM, Del Giudice I, Bardi A, Melandri A, García-Jacobo RE, Cura F, Raponi S, Ilari C, Cafforio L, Piciocchi A, Arena V, Reda G, Albano F, Molica S, Sportoletti P, Trentin L, Marchetti M, Nanni M, Peragine N, Mariglia P, Vignetti M, Guarini A, Mauro FR, Foà R, Cuneo A
20213452976810.1182/bloodadvances.2021004649Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy.Blood advancesEfficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P, Di Bona E, Borlenghi E, Autore F, Levato L, Finizio O, Mancini V, D'Ardia S, Schlenk RF, Melillo L, Fumagalli M, Fiedler W, Beltrami G, Fracchiolla NS, Bernardi M, Fazi P, Annibali O, Mayer K, Voso MT, Vignetti M
20213451434310.1097/HS9.0000000000000639Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network.HemaSphereMantoan B, Genuardi E, Ferrante M, Della Starza I, Ciabatti E, Grassi S, De Novi LA, Cavalli M, Mannu C, Gazzola A, Bomben R, Degan M, Alessandria B, Pott C, Delfau-Larue MH, García-Sanz R, Agostinelli C, Gattei V, Galimberti S, Del Giudice I, Gaidano G, Ladetto M, Ferrero S, Drandi D
20213451371410.3389/fonc.2021.739171Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.Frontiers in oncologySpecchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, Tiribelli M, Stagno F, Caocci G, Martino B, Luciano L, Pizzuti M, Gozzini A, Scortechini AR, Albano F, Bergamaschi M, Capodanno I, Patriarca A, Fava C, Rege-Cambrin G, Sorà F, Galimberti S, Bocchia M, Binotto G, Reddiconto G, DiTonno P, Maggi A, Sanpaolo G, De Candia MS, Giai V, Abruzzese E, Miggiano MC, La Barba G, Pietrantuono G, Guella A, Levato L, Mulas O, Saccona F, Rosti G, Musto P, Di Raimondo F, Pane F, Baccarani M, Saglio G, Ciccone G
20213451062410.1002/onco.13974Changes in Cancer Patients' and Caregivers' Disease Perceptions While Receiving Early Palliative Care: A Qualitative and Quantitative Analysis.The oncologistBorelli E, Bigi S, Potenza L, Eliardo S, Artioli F, Mucciarini C, Cottafavi L, Cagossi K, Razzini G, Cruciani M, Pietramaggiori A, Fantuzzi V, Lombardo L, Ferrari U, Ganfi V, Lui F, Odejide O, Cacciari C, Porro CA, Zimmermann C, Efficace F, Bruera E, Luppi M, Bandieri E
20213446190910.1186/s12955-021-01820-xGeneral Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition.Health and quality of life outcomesArraras JI, Nolte S, Liegl G, Rose M, Manterola A, Illarramendi JJ, Zarandona U, Rico M, Teiejria L, Asin G, Hernandez I, Barrado M, Vera R, Efficace F, Giesinger JM,
20213440208810.1002/hon.2913Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.Hematological oncologyAnsuinelli M, Della Starza I, Lauretti A, Elia L, Siravo V, Messina M, De Novi LA, Taherinasab A, Canichella M, Guarini A, Foà R, Chiaretti S
20213435564410.1080/10428194.2021.1961237Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center.Leukemia & lymphomaAl-Hadad SA, Al-Jadiry MF, Ghali HH, Al-Badri SAF, Al-Saeed RM, Al-Darraji AF, Sabhan AH, Fadhil SA, Hussein HM, Abed WM, Ameen NA, Sahan JKA, Jaafar GQ, Abed AR, Mohamed S, Moleti ML, Piciocchi A, Foà R, Testi AM
20213429782910.1182/blood.2021011822Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.BloodPuzzolo MC, Radice G, Peragine N, de Propris MS, Mariglia P, Vignetti M, Vitale A, Bassan R, Annunziata M, Gaidano G, Rambaldi A, Chiaretti S, Guarini A, Foà R
20213425453010.2217/fon-2021-0388AMELIORATE: early intensification in -mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.Future oncology (London, England)Mannelli F, Gianfaldoni G, Guglielmelli P, Buccisano F, Caporale R, Chiarini M, Rossi G, Venditti A, Fazi P, Crea E, Piciocchi A, Voso MT, Vignetti M, Amadori S, Vannucchi AM
20213421939510.1002/cam4.4111International perspectives on suboptimal patient-reported outcome trial design and reporting in cancer clinical trials: A qualitative study.Cancer medicineRetzer A, Calvert M, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Kyte D
20213414557210.1111/bjh.17637Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.British journal of haematologyTesti AM, Mohamed S, Diverio D, Piciocchi A, Menna G, Rizzari C, Timeus F, Micalizzi C, Lo Nigro L, Santoro N, Masetti R, Micheletti MV, Ziino O, Onofrillo D, Ladogana S, Putti C, Pierani P, Arena V, Zecca M, Foà R, Locatelli F
20213412564210.1080/17474086.2021.1943352Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review.Expert review of hematologyEfficace F, Cannella L, Breccia M, Olivieri J, Platzbecker U, Vignetti M
20213407585210.1080/17474086.2021.1938534Measuring prognosis in chronic myeloid leukemia: what's new?Expert review of hematologyBreccia M, Efficace F, Scalzulli E, Ciotti G, Maestrini G, Colafigli G, Martelli M
20213404807210.1002/ajh.26253Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.American journal of hematologyPiciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, Bonifacio M, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, Vignetti M
20213400203010.1038/s41375-021-01292-4Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study.LeukemiaBreccia M, Pregno P, Castagnetti F, Bonifacio M, Tiribelli M, Gozzini A, Scortechini AR, Luciano L, Martino B, Stagno F, Caocci G, La Barba G, Pizzuti M, Ciccone G, Saglio G, Specchia G
20213393703810.3389/fonc.2021.637186TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.Frontiers in oncologyPuzzolo MC, Del Giudice I, Peragine N, Mariglia P, De Propris MS, Cappelli LV, Trentin L, Reda G, Cuneo A, Molica S, Piciocchi A, Arena V, Mauro FR, Guarini A, Foà R
20213389058010.2196/25271The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study.JMIR research protocolsEfficace F, Breccia M, Fazi P, Cottone F, Holzner B, Vignetti M
20213384043710.1016/j.jval.2020.11.004Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchGiesinger JM, Efficace F, Aaronson N, Calvert M, Kyte D, Cottone F, Cella D, Gamper EM
20213380250210.3390/cancers13051083Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.CancersBuccisano F, Palmieri R, Piciocchi A, Maurillo L, Del Principe MI, Paterno G, Soddu S, Cerretti R, De Angelis G, Mariotti B, Irno Consalvo MA, Conti C, Fraboni D, Divona M, Ottone T, Lavorgna S, Panetta P, Voso MT, Arcese W, Venditti A
20213378889310.1371/journal.pone.0248755Different semantic and affective meaning of the words associated to physical and social pain in cancer patients on early palliative/supportive care and in healthy, pain-free individuals.PloS oneBorelli E, Bigi S, Potenza L, Artioli F, Eliardo S, Mucciarini C, Cagossi K, Razzini G, Pasqualini A, Lui F, Ferlazzo F, Cruciani M, Bruera E, Efficace F, Luppi M, Cacciari C, Porro CA, Bandieri E
20213375322810.1016/j.jclinepi.2021.03.015The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.Journal of clinical epidemiologyGamper EM, Cottone F, Sommer K, Norman R, King M, Breccia M, Caocci G, Patriarca A, Palumbo GA, Stauder R, Niscola P, Platzbecker U, Caers J, Vignetti M, Efficace F
20213373946110.1002/hon.2861Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.Hematological oncologyRigolin GM, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G, Zamprogna G, Cibien F, Vitagliano O, Coscia M, Farina L, Gaidano G, Murru R, Varettoni M, Paolini R, Sportoletti P, Pietrasanta D, Molinari AL, Quaglia FM, Laurenti L, Marasca R, Marchetti M, Mauro FR, Crea E, Vignetti M, Gentile M, Montillo M, Foà R, Cuneo A,
20213367765410.1007/s00277-021-04477-0Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.Annals of hematologyScalzulli E, Caocci G, Efficace F, Rizzo L, Colafigli G, Di Prima A, Pepe S, Fegatelli DA, Carmosino I, Diverio D, Latagliata R, La Nasa G, Martelli M, Foà R, Breccia M
20213365519910.1097/HS9.0000000000000543Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia.HemaSphereDella Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, Campeggio M, De Novi LA, Soscia R, Oggioni C, Mussolin L, Biondi A, Guarini A, Valsecchi MG, Conter V, Biffi A, Basso G, Foà R, Cazzaniga G
20213361843810.1111/bjh.17334Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study.British journal of haematologyLucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, Patriarca A, Carli G, Barcellini W, Celli M, Consoli U, Valeri F, Santoro C, Crea E, Vignetti M, Paoloni F, Gigliotti CL, Boggio E, Dianzani U, Giardini I, Carpenedo M, Rodeghiero F, Fanin R, Zaja F,
20213355467210.1080/17474086.2021.1886918Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Expert review of hematologyEfficace F, Vignetti M, Sparano F, Scalzulli E, Breccia M
20213353815010.3324/haematol.2020.260935A multicenter total therapy strategy for adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.HaematologicaChiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A, Fazi P, Di Raimondo F, Santoro L, Fabbiano F, Califano C, Martinelli G, Ronco F, Ferrara F, Cascavilla N, Bigazzi C, Tedeschi A, Sica S, Di Renzo N, Melpignano A, Beltrami G, Vignetti M, Foa R
20213352861110.1007/s00277-020-04374-yDaratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.Annals of hematologyVozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, Piciocchi A, Andriani A, Annibali O, De Rosa L, Cimino G, La Verde G, De Stefano V, Cantonetti M, di Toritto TC, Petrucci MT
20213351803210.1016/j.jval.2020.10.017Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchEfficace F, Collins GS, Cottone F, Giesinger JM, Sommer K, Anota A, Schlussel MM, Fazi P, Vignetti M
20213346283710.1002/hon.2837Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia.Hematological oncologyFresa A, Autore F, Innocenti I, Piciocchi A, Tomasso A, Morelli F, Sorà F, Sica S, De Stefano V, Laurenti L
20213338886010.1007/s00277-020-04392-wLow-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.Annals of hematologyCaocci G, Mulas O, Capodanno I, Bonifacio M, Annunziata M, Galimberti S, Luciano L, Tiribelli M, Martino B, Castagnetti F, Binotto G, Pregno P, Stagno F, Abruzzese E, Bocchia M, Gozzini A, Albano F, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, Baratè C, De Gregorio F, Stella R, Gugliotta G, Pirillo F, Trawinska MM, Sicuranza A, Cattaneo D, Attolico I, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G
20213328499910.1002/ajh.26066Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.American journal of hematologyTesti AM, Canichella M, Vitale A, Piciocchi A, Guarini A, Starza ID, Cavalli M, De Propris MS, Messina M, Elia L, Moleti ML, Martino B, Luppi M, D'Aloisio M, Candoni A, Conter V, Fazi P, Vignetti M, Chiaretti S, Foà R
20213327052910.1089/jpm.2020.0396Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study.Journal of palliative medicineCartoni C, Breccia M, Giesinger JM, Baldacci E, Carmosino I, Annechini G, Palumbo G, Armiento D, Niscola P, Tendas A, Brunetti GA, Minotti C, Marini MG, Reale L, Martone N, Martelli M, Efficace F
20213316575110.1007/s11523-020-00769-zDeveloping Symptom Lists for People with Cancer Treated with Targeted Therapies.Targeted oncologySodergren SC, Wheelwright SJ, Fitzsimmons D, Efficace F, Sprangers M, Fayers P, Harle A, Schmidt H, Bottomley A, Darlington AS, Benson C, Bredart A, Hentschel L, Arraras JI, Ioannidis G, Leahy M, Lugowska I, Nicolatou-Galitis O, Petranovic D, Rohde GE, Vassiliou V, Johnson CD,
20213315335510.1080/10428194.2020.1838509Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.Leukemia & lymphomaEfficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, Bonifacio M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sorà F, Castagnetti F, Baccarani M, Vignetti M, Rosti G
20213315069110.1002/onco.13587COVID-19 Pandemic and Cancer: The Importance of Early Palliative Care.The oncologistPotenza L, Luppi M, Efficace F, Bruera E, Bandieri E
20213309435710.1007/s00520-020-05840-zA qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRiva S, Efficace F, Di Maio M, Bryce J, Del Campo L, De Lorenzo F, Frontini L, Giannarelli D, Gitto L, Iannelli E, Jommi C, Montesarchio V, Traclò F, Vaccaro CM, Arenare L, Canzanella G, Gimigliano A, Romano F, Savio A, Sparavigna L, Piccirillo MC, Guizzaro L, Gallo C, Perrone F
20213297590410.1002/cncy.22344Human herpesvirus-8-positive primary effusion lymphoma in HIV-negative patients: Single institution case series with a multidisciplinary characterization.Cancer cytopathologyRossi G, Cozzi I, Della Starza I, De Novi LA, De Propris MS, Gaeta A, Petrucci L, Pulsoni A, Pulvirenti F, Ascoli V
20213283560110.1089/jpm.2020.0159Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment.Journal of palliative medicinePilz MJ, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, Holzner B, van Leeuwen M, Loth FLC, Petersen MA, Ramage J, Tomaszewski KA, Young T, Giesinger JM
20213280867210.1111/bjh.17018Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.British journal of haematologyGurnari C, Breccia M, Di Giuliano F, Scalzulli E, Divona M, Piciocchi A, Cicconi L, De Bellis E, Venditti A, Del Principe MI, Arcese W, Lo-Coco F, Garaci F, Voso MT
20213246714510.3324/haematol.2020.247973Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.HaematologicaChiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Albertini Petroni G, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foà R
20213187932810.3324/haematol.2019.231704Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network.HaematologicaDel Principe MI, Buzzatti E, Piciocchi A, Forghieri F, Bonifacio M, Lessi F, Imbergamo S, Orciuolo E, Rossi G, Fracchiolla N, Trappolini S, Neri B, Sarlo C, Zappasodi P, Dargenio M, Cefalo M, Irno-Consalvo MA, Conti C, Paterno G, De Angelis G, Sciumè M, Della Starza I, Venditti A, Foà R, Guarini AR
20203326295110.3389/fonc.2020.594129UK Experience of an Alternative ATO Dosing Regimen in APL.Frontiers in oncologyRussell N, Dillon R
20203324244610.1016/S2352-3026(20)30292-1Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review.The Lancet. HaematologyChakraborty R, Cannella L, Cottone F, Efficace F
20203324244310.1016/S2352-3026(20)30323-9Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.The Lancet. HaematologyTacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V, Testoni N, Spadano A, Terragna C, Pescosta N, Marzocchi G, Cellini C, Galieni P, Ronconi S, Gobbi M, Catalano L, Lazzaro A, De Sabbata G, Cangialosi C, Ciambelli F, Musto P, Elice F, Cavo M,
20203320569410.1080/17474086.2021.1852924Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.Expert review of hematologyBreccia M, Efficace F, Colafigli G, Scalzulli E, Di Prima A, Martelli M, Foà R
20203318722910.3390/cancers12113334Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.CancersRamadan SM, Suciu S, Stevens-Kroef MJPL, Willemze R, Amadori S, de Witte T, Löwenberg B, Muus P, Labar B, Meert L, de Schaetzen G, Meloni G, Leone G, Vignetti M, Marie JP, Lübbert M, Baron F
20203313125910.3324/haematol.2019.235705High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).HaematologicaMauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, Angelucci E, Re F, Liberati AM, Tedeschi A, Reda G, Pietrasanta D, Gozzetti A, Battistini R, Del Poeta G, Musolino C, Nanni M, Piciocchi A, Vignetti M, Neri A, Albano F, Cuneo A, Del Giudice I, Della Starza I, De Propris MS, Raponi S, Guarini AR, Foà R
20203311059010.7189/jogh.10.020507Screening policies, preventive measures and in-hospital infection of COVID-19 in global surgical practices.Journal of global healthBellato V, Konishi T, Pellino G, An Y, Piciocchi A, Sensi B, Siragusa L, Khanna K, Pirozzi BM, Franceschilli M, Campanelli M, Efetov S, Sica GS,
20203309161610.1016/j.leukres.2020.106462Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia.Leukemia researchDe Bellis E, Ottone T, Mercante L, Falconi G, Cugini E, Consalvo MI, Travaglini S, Paterno G, Piciocchi A, Rossi ELL, Gurnari C, Maurillo L, Buccisano F, Arcese W, Voso MT
20203308586010.1056/NEJMoa2016272Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.The New England journal of medicineFoà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S,
20203305412410.3324/haematol.2020.262071Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.HaematologicaPeragine N, De Propris MS, Intoppa S, Milani ML, Mariglia P, Mauro FR, Raponi S, Soddu S, Cuneo A, Rigolin GM, Del Giudice I, Foà R, Guarini A
20203304905410.1182/bloodadvances.2020002904Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Blood advancesVoso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F
20203299824310.3390/ijerph17197097Independent Research on Cancer Pain Management in the Setting of Early Palliative Care: A Flywheel to Counteract General Opioid Misuse and Abuse.International journal of environmental research and public healthBandieri E, Potenza L, Efficace F, Bruera E, Luppi M
20203296959710.1002/cam4.3470Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.Cancer medicineCuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P,
20203293595510.23736/S1973-9087.20.06412-6Treatments in neurogenic bowel dysfunctions: evidence reviews and clinical recommendations in adults.European journal of physical and rehabilitation medicineMusco S, Bazzocchi G, Martellucci J, Amato MP, Manassero A, Putignano D, Lopatriello S, Cafiero D, Paoloni F, Del Popolo G
20203287308810.1080/17474086.2020.1816819The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Expert review of hematologyColafigli G, Scalzulli E, Pepe S, Di Prima A, Efficace F, Martelli M, Foà R, Breccia M
20203284646510.1002/cam4.3335Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.Cancer medicineMouillet G, Efficace F, Thiery-Vuillemin A, Charton E, Van Hemelrijck M, Sparano F, Anota A
20203284371610.1038/s41375-020-01032-0COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.LeukemiaBreccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P, Soddu S, Martino B, Palandri F, Siragusa S, Albano F, Passamonti F, Vignetti M, Vannucchi AM
20203276736710.1002/bjs.11800Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic.The British journal of surgeryBellato V, Konishi T, Pellino G, An Y, Piciocchi A, Sensi B, Siragusa L, Khanna K, Pirozzi BM, Franceschilli M, Campanelli M, Efetov S, Sica GS,
20203276275510.1186/s12955-020-01504-yInvestigating the association between physicians self-efficacy regarding communication skills and risk of "burnout".Health and quality of life outcomesMesserotti A, Banchelli F, Ferrari S, Barbieri E, Bettelli F, Bandieri E, Giusti D, Catellani H, Borelli E, Colaci E, Pioli V, Morselli M, Forghieri F, Galeazzi GM, Marasca R, Bigi S, D'Amico R, Martin P, Efficace F, Luppi M, Potenza L
20203269733710.1002/ajh.25942Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.American journal of hematologyMannelli F, Gianfaldoni G, Bencini S, Piccini M, Cutini I, Bonetti MI, Scappini B, Pancani F, Ponziani V, Chiarini M, Borlenghi E, Bassan R, Rossi G, Bosi A
20203262175410.1111/bjh.16996The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.British journal of haematologyPiciocchi A, Messina M, Soddu S, La Sala E, Paoloni F, Giuliani G, Marino MR, Petrelli C, Gorreo Renzulli L, Fazi P, Vignetti M
20203262084010.1038/s41375-020-0953-3How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey.LeukemiaPalandri F, Piciocchi A, De Stefano V, Breccia M, Finazzi G, Iurlo A, Fazi P, Soddu S, Martino B, Siragusa S, Albano F, Passamonti F, Vignetti M, Vannucchi AM
20203260661510.2147/PPA.S249079Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS).Patient preference and adherencePeipert JD, Badawy SM, Baik SH, Oswald LB, Efficace F, Garcia SF, Mroczek DK, Wolf M, Kaiser K, Yanez B, Cella D
20203258839410.1007/s12185-020-02920-yHigh serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity.International journal of hematologyCaocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F
20203256283710.1016/j.jclinepi.2020.06.016Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies.Journal of clinical epidemiologyCottone F, Collins GS, Anota A, Sommer K, Giesinger JM, Kieffer JM, Aaronson NK, Van Steen K, Charton E, Castagnetti F, Fazi P, Vignetti M, Cella D, Efficace F
20203255753110.1111/bjh.16877Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.British journal of haematologyBreccia M, Vignetti M, Annibali O, Cottone F, Luppi M, Borlenghi E, Rodeghiero F, Efficace F
20203251411010.1038/s41408-020-0333-2Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.Blood cancer journalCaocci G, Mulas O, Capodanno I, Abruzzese E, Iurlo A, Luciano L, Albano F, Annunziata M, Tiribelli M, Bonifacio M, Galimberti S, Castagnetti F, Sgherza N, Stagno F, Gozzini A, Orlandi EM, Luzi D, Binotto G, Pregno P, Fozza C, Efficace F, Simula MP, Trawinska MM, Cattaneo D, De Gregorio F, Attolico I, Stella R, Scaffidi L, Baratè C, Gugliotta G, Scalzulli E, Elena C, Pirillo F, Foà R, Breccia M, Nasa G
20203247461910.1007/s00277-020-04102-6Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.Annals of hematologyMulas O, Caocci G, Stagno F, Bonifacio M, Annunziata M, Luciano L, Orlandi EM, Abruzzese E, Sgherza N, Martino B, Albano F, Galimberti S, Pregno P, Bocchia M, Castagnetti F, Tiribelli M, Binotto G, Gozzini A, Capodanno I, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, De Gregorio F, Elena C, Trawinska MM, Cattaneo D, Attolico I, Baratè C, Pirillo F, Sicuranza A, Gugliotta G, Stella R, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G
20203245840910.1007/s11136-020-02536-zEORTC QLU-C10D value sets for Austria, Italy, and Poland.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationGamper EM, King MT, Norman R, Efficace F, Cottone F, Holzner B, Kemmler G,
20203244141910.1111/ejh.13454Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".European journal of haematologyMazzucconi MG, Baldacci E, Latagliata R, Breccia M, Paoloni F, Di Veroli A, Cedrone M, Anaclerico B, Villivà N, Porrini R, Montefusco E, Andriani A, Montanaro M, Scaramucci L, Spadea A, Rago A, Cimino G, Spirito F, Santoro C
20203241028110.1111/bjh.16654Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.British journal of haematologyRochau U, Stojkov I, Conrads-Frank A, Borba HH, Koinig KA, Arvandi M, van Marrewijk C, Garelius H, Germing U, Symeonidis A, Sanz GF, Fenaux P, de Witte T, Efficace F, Siebert U, Stauder R
20203238923310.1016/j.jval.2020.02.007Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchGiesinger JM, Blazeby J, Aaronson NK, Sprangers M, Fayers P, Sparano F, Rees J, Anota A, Wan C, Pezold M, Isharwal S, Cottone F, Efficace F,
20203233363910.1002/cam4.3018Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making.Cancer medicineVan Hemelrijck M, Sparano F, Moris L, Beyer K, Cottone F, Sprangers M, Efficace F
20203230978410.1097/HS9.0000000000000347Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.HemaSphereDrandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E
20203223309510.1002/ajh.25795Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study.American journal of hematologyBaron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, Fazi P, Vignetti M, Marie JP, Chiusolo P, van der Velden W, La Sala E, Vitolo U, Thomas X, Lefrère F, Di Raimondo F, Bourhis JH, Specchia G, Guimarães JE, Allione B, Vrhovac R, Ferrara F, Stevens-Kroef M, Meert L, de Witte T, Willemze R, Amadori S, Suciu S
20203208644710.1038/s41375-020-0746-8The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index.LeukemiaEfficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M
20203208082910.1111/bjh.16532Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.British journal of haematologyChakraborty R, Efficace F
20203206459510.1111/bjh.16434Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.British journal of haematologyRaponi S, Ilari C, Della Starza I, Cappelli LV, Cafforio L, Piciocchi A, Arena V, Mariglia P, Mauro FR, Gentile M, Cutrona G, Moia R, Favini C, Morabito F, Rossi D, Gaidano G, Guarini A, Del Giudice I, Foà R
20203192895210.1016/j.clml.2019.12.004Early Palliative Care: A Necessary Intervention for Patients Ineligibile to Approved Potentially Life-saving CAR T-cell Therapy.Clinical lymphoma, myeloma & leukemiaPotenza L, Luppi M, Efficace F, Bruera E, Bandieri E
20203179771110.1080/10428194.2019.1699078WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.Leukemia & lymphomaFalconi G, Fabiani E, Ottone T, Piciocchi A, Lavorgna S, Criscuolo M, Fianchi L, Gurnari C, Postorino M, Picardi A, Palmieri R, Lo-Coco F, Voso MT
20203178201610.1007/s11136-019-02369-5Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationSommer K, Cottone F, Aaronson NK, Fayers P, Fazi P, Rosti G, Angelucci E, Gaidano G, Venditti A, Voso MT, Baccarani M, Vignetti M, Efficace F
20203177682710.1007/s11136-019-02367-7Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationCharton E, Cuer B, Cottone F, Efficace F, Touraine C, Hamidou Z, Fiteni F, Bonnetain F, Woronoff-Lemsi MC, Bascoul-Mollevi C, Anota A
20203168656110.1080/10428194.2019.1675881The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.Leukemia & lymphomaMateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J
20203163944510.1016/j.jclinepi.2019.10.003Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.Journal of clinical epidemiologyGiesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B,
20203161162410.1038/s41375-019-0589-3Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.LeukemiaCicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F
20203159379710.1016/j.jclinepi.2019.09.028Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core-an adaptive measure of core quality of life domains in oncology clinical practice and research.Journal of clinical epidemiologyGiesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B,
20203155806710.1080/10428194.2019.1668938Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with fusion transcript.Leukemia & lymphomaFazio F, Barberi W, Cazzaniga G, Fazio G, Messina M, Della Starza I, De Propris MS, Mancini F, Mohamed S, Del Giudice I, Chiaretti S, Moleti ML, Guarini A, Foà R, Testi AM
20203147779810.1038/s41375-019-0563-0Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.LeukemiaEfficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G
20203125373310.1136/bmjspcare-2018-001755Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry.BMJ supportive & palliative careServadio M, Cottone F, Sommer K, Oerlemans S, van de Poll-Franse L, Efficace F
20203124897310.3324/haematol.2019.220657First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.HaematologicaLarocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangiolosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hájek R, Boccadoro M, Bringhen S
20203120115210.1136/bmjspcare-2019-001794Early versus delayed palliative/supportive care in advanced cancer: an observational study.BMJ supportive & palliative careBandieri E, Banchelli F, Artioli F, Mucciarini C, Razzini G, Cruciani M, Potenza L, D'Amico R, Efficace F, Bruera E, Luppi M
20203109763410.3324/haematol.2019.221333Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.HaematologicaBaron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S
20193186941210.1182/bloodadvances.2019000865Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.Blood advancesBaccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi P, Fozza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G
20193171905110.1136/bmjspcare-2019-001902Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review.BMJ supportive & palliative careSparano F, Aaronson NK, Sprangers MAG, Fayers P, Pusic A, Kieffer JM, Cottone F, Rees J, Pezold M, Anota A, Charton E, Vignetti M, Wan C, Blazeby J, Efficace F
20193170806810.1016/j.jval.2019.06.004Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchEfficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, Groenvold M, Caocci G, Lo Coco F, Gaidano G, Niscola P, Baccarani M, Rosti G, Venditti A, Angelucci E, Fazi P, Vignetti M, Giesinger J
20193160641810.1016/S1470-2045(19)30641-2Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies.The Lancet. OncologyEfficace F, Vignetti M
20193155557610.3389/fonc.2019.00689Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?Frontiers in oncologyDel Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, Cappelli LV, Ilari C, Cafforio L, Guarini A, Foà R
20193152114910.1186/s12894-019-0518-9Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.BMC urologyVan Hemelrijck M, Sparano F, Josephs D, Sprangers M, Cottone F, Efficace F
20193150113010.1136/bmjopen-2019-031485Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol.BMJ openRiva S, Bryce J, De Lorenzo F, Del Campo L, Di Maio M, Efficace F, Frontini L, Giannarelli D, Gitto L, Iannelli E, Jommi C, Montesarchio V, Traclò F, Vaccaro CM, Gallo C, Perrone F
20193144823010.3389/fonc.2019.00726Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.Frontiers in oncologyDella Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA, Soscia R, Messina M, Vitale A, Guarini A, Foà R
20193139560010.1182/blood.2018886960GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.BloodVenditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S
20193138693210.1016/j.leukres.2019.106191Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.Leukemia researchFalconi G, Fabiani E, Criscuolo M, Fianchi L, Finelli C, Cerqui E, Pelosi E, Screnci M, Gurnari C, Zangrilli I, Postorino M, Laurenti L, Piciocchi A, Testa U, Lo-Coco F, Voso MT
20193136415310.1111/bjh.16123Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.British journal of haematologyInnocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L
20193131779310.1080/17474086.2019.1645005Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma.Expert review of hematologyNiscola P, Scaramucci L, Efficace F
20193129805910.1080/10428194.2019.1639170Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.Leukemia & lymphomaBassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R
20193117956110.1002/ajh.25555Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.American journal of hematologyLoscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM
20193116865210.1007/s00277-019-03724-9Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.Annals of hematologyScalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M
20193112441510.2217/pgs-2018-0202Genomic profiling and predicting treatment response in acute myeloid leukemia.PharmacogenomicsIsidori A, Loscocco F, Curti A, Amadori S, Visani G
20193107926410.1007/s00277-019-03706-xTen-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.Annals of hematologyMolica M, Colafigli G, Scalzulli E, Alunni Fegatelli D, Chiatamone Ranieri S, Rizzo L, Diverio D, Efficace F, Latagliata R, Foà R, Breccia M
20193105397110.1007/s00520-019-04743-yPain and related complaints in patients with acute leukemia: time for simultaneous care in hemato-oncology.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerNiscola P, Tendas A, Mazzone C, Efficace F
20193105055110.1080/10428194.2019.1607325Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.Leukemia & lymphomaDella Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A
20193099787310.1080/10428194.2018.1519810Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients.Leukemia & lymphomaMoleti ML, Al-Jadiry MF, Shateh WA, Al-Darraji AF, Mohamed S, Uccini S, Piciocchi A, Foà R, Testi AM, Al-Hadad S
20193083888310.2217/cer-2018-0092Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?Journal of comparative effectiveness researchSparano F, Aaronson NK, Cottone F, Piciocchi A, La Sala E, Anota A, Deliu N, Kieffer JM, Efficace F
20193083374110.1038/s41409-019-0497-1Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol.Bone marrow transplantationLa Rocca U, Perrone MP, Piciocchi A, Cinti P, Barberi W, Gozzer M, Baftii MS, Torelli GF, Quattrocchi L, Gesuiti P, Lattanzi R, Cavallari C, Ricci R, Laurenti L, Foà R, Girelli G, Iori AP
20193078413210.1002/pds.4756Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes.Pharmacoepidemiology and drug safetyCottone F, Anota A, Bonnetain F, Collins GS, Efficace F
20193077615610.1111/ejh.13222Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.European journal of haematologyPiciocchi A, Sargentini V, Cotugno F, Bontempi K, Beltrami G, Di Tucci AA, Riva M, Quaresmini G, Vallisa D, Finelli C, Borin L, Fazi P, Vignetti M, Angelucci E
20193065944910.1007/s11136-018-02097-2Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationCottone F, Deliu N, Collins GS, Anota A, Bonnetain F, Van Steen K, Cella D, Efficace F
20193063562810.1038/s41375-018-0352-1Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931- July 15, 2018.LeukemiaAmadori S, Arcese W, Avvisati G, Gale RP, Lo-Coco F
20193062642510.1186/s13045-018-0691-4Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.Journal of hematology & oncologySaltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R
20193057377610.1038/s41375-018-0325-4Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.LeukemiaEfficace F, Breccia M, Avvisati G, Cottone F, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Luppi M, Romani C, Sborgia M, D'Ardia S, Nobile F, Cantore N, Crugnola M, Nadali G, Vignetti M, Amadori S, Lo Coco F
20193041164610.1080/17474086.2019.1547189Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.Expert review of hematologyEfficace F, Cottone F
20193029133810.1038/s41375-018-0284-9Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.LeukemiaFalconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, Finelli C, Cerqui E, Ottone T, Molteni A, Parma M, Santarone S, Candoni A, Sica S, Leone G, Lo-Coco F, Voso MT
20193019034210.3324/haematol.2018.196055Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.HaematologicaFedullo AL, Messina M, Elia L, Piciocchi A, Gianfelici V, Lauretti A, Soddu S, Puzzolo MC, Minotti C, Ferrara F, Martino B, Chiusolo P, Calafiore V, Paolini S, Vignetti M, Vitale A, Guarini A, Foà R, Chiaretti S
20193018823010.1080/10428194.2018.1499906IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.Leukemia & lymphomaGianfelici V, Messina M, Paoloni F, Peragine N, Lauretti A, Fedullo AL, Di Giacomo F, Vignetti M, Vitale A, Guarini A, Chiaretti S, Foà R
20192978573410.1111/bjh.15405Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.British journal of haematologyRaponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R
20183053795510.1186/s12955-018-1055-zDistribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review.Health and quality of life outcomesOusmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Brédart A, Mollevi C, Anota A
20183050284910.1053/j.seminhematol.2018.02.006Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.Seminars in hematologyDel Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A
20183044793110.1016/j.critrevonc.2018.09.008Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.Critical reviews in oncology/hematologyD'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F
20183041988910.1186/s12885-018-5036-8International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.BMC cancerSztankay M, Aaronson NK, Arraras JI, Basso U, Bumbasirevic U, Efficace F, Giesinger JM, Johnson CD, van Leeuwen M, Oberguggenberger AS, Sosnowski R, Young T, Holzner B,
20183036140910.1136/bmjopen-2018-025054Evaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocol.BMJ openDeliu N, Cottone F, Collins GS, Anota A, Efficace F
20183023938710.1097/SPC.0000000000000386How should we assess patient-reported outcomes in the onco-hematology clinic?Current opinion in supportive and palliative careCannella L, Efficace F, Giesinger J
20183002915610.1016/j.leukres.2018.07.002Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.Leukemia researchGurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT, ,
20182995087510.2147/CEOR.S152437Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia.ClinicoEconomics and outcomes research : CEORQerimi V, Nestorovska AK, Sterjev Z, Genadieva-Stavric S, Suturkova L
20182993210510.3390/cancers10070211Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach.CancersIsidori A, Loscocco F, Ciciarello M, Corradi G, Lecciso M, Ocadlikova D, Parisi S, Salvestrini V, Amadori S, Visani G, Curti A
20182992615610.1007/s00277-018-3396-4Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.Annals of hematologyBaron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S
20182991450910.1186/s12955-018-0953-4A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.Health and quality of life outcomesEfficace F, Boccadoro M, Palumbo A, Petrucci MT, Cottone F, Cannella L, Zamagni E, Niscola P, Kyriakou C, Caravita T, Offidani M, Mandelli F, Cavo M
20182991018010.1016/j.clml.2018.05.019Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.Clinical lymphoma, myeloma & leukemiaMina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S
20182989895510.1182/blood-2018-03-835413Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.BloodRossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W
20182984587610.1080/14740338.2018.1480719Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.Expert opinion on drug safetyBreccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G
20182967595510.1111/bjh.15251Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.British journal of haematologyChiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R
20182967579210.1007/s00432-018-2641-5Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.Journal of cancer research and clinical oncologyCerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F
20182967450410.3324/haematol.2018.189837Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.HaematologicaCuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P,
20182963331210.1002/ajh.25102Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.American journal of hematologyCaocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M
20182957250610.1038/s41375-018-0089-xHealth-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.LeukemiaStauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T
20182956050210.1007/s00520-018-4137-xPatient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerSparano F, Cavo M, Niscola P, Caravita T, Efficace F
20182950215310.1007/s00520-018-4124-2Sexual health in patients with hematological malignancies: a neglected issue.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerNiscola P, Efficace F, Abruzzese E
20182943112310.1136/bmjopen-2017-017282Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.BMJ openRetzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D
20182936508610.1093/annonc/mdy021Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.Annals of oncology : official journal of the European Society for Medical OncologyRaponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R
20182927914510.1016/j.ejrad.2017.10.025Diffusion-weighted magnetic resonance imaging in painful bone metastases: Using quantitative apparent diffusion coefficient as an indicator of effectiveness of single fraction versus multiple fraction radiotherapy.European journal of radiologyMusio D, De Francesco I, Galdieri A, Marsecano C, Piciocchi A, Napoli A, De Felice F, Tombolini V
20182923196910.1002/cncr.31193Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.CancerEfficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F
20182920520410.1038/tpj.2017.48MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.The pharmacogenomics journalVisani G, Loscocco F, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A
20182919172210.1016/j.jpainsymman.2017.11.023Early Palliative Care in Patients With Hematological Malignancies: Where Do We Go From Here?Journal of pain and symptom managementNiscola P, Tendas A, Efficace F
20182912759610.1007/s11136-017-1718-yInternational development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationvan de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F,
20182892424310.1038/leu.2017.292Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.LeukemiaGiudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R
20182885742410.1002/pon.4548A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important.Psycho-oncologyGiesinger JM, Aaronson NK, Arraras JI, Efficace F, Groenvold M, Kieffer JM, Loth FL, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B,
20172904737910.1186/s12955-017-0788-4Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.Health and quality of life outcomesBreccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, Efficace F
20172902028610.1093/cid/cix690Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey.Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaGirmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scimè R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A,
20172879162210.1007/s40265-017-0795-0Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.DrugsSyed YY
20172869432410.1182/blood-2017-03-737403Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?BloodEfficace F, Gaidano G, Lo-Coco F
20172865580810.3324/haematol.2017.166280Chronic myeloid leukemia: room for improvement?HaematologicaBaccarani M, Pane F, Rosti G, Russo D, Saglio G
20172859628210.3324/haematol.2016.156901Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.HaematologicaLaurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R
20172853569510.1080/10428194.2017.1330476Are chronic myeloid leukemia patients ready to stop long-term treatment?Leukemia & lymphomaBreccia M, Efficace F
20172849033810.1186/s12955-017-0670-4International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.Health and quality of life outcomesvan Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK, , ,
20172843988710.1111/bjh.14721Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.British journal of haematologyMessina M, Chiaretti S, Fedullo AL, Piciocchi A, Puzzolo MC, Lauretti A, Gianfelici V, Apicella V, Fazi P, Te Kronnie G, Testi AM, Vitale A, Guarini A, Foà R
20172837051010.1111/ejh.12887Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.European journal of haematologyGoel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F
20172809356510.1038/leu.2017.20Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.LeukemiaBaccarani M
20172794178210.1038/bmt.2016.308Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.Bone marrow transplantationBuccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A
201727915304Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?Medical mycologyDragonetti G, Criscuolo M, Fianchi L, Pagano L
20172788103910.1080/10428194.2016.1258698Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.Leukemia & lymphomaMauro FR, Carella AM, Molica S, Paoloni F, Liberati AM, Zaja F, Belsito V, Cortellezzi A, Rizzi R, Tosi P, Spriano M, Ferretti A, Nanni M, Marinelli M, De Propris MS, Orlando SM, Vignetti M, Cuneo A, Guarini AR, Foà R
20172778967710.3324/haematol.2016.153130Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.HaematologicaSelleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F
201627913477The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.Hematology. American Society of Hematology. Education ProgramEfficace F, Cannella L
20163030220910.2217/ijh-2016-0013Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco.International journal of hematologic oncologyLo-Coco F
201627448405Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerEfficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, Rosti G, Baccarani M
20162765526310.1136/bmjopen-2016-012863Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol.BMJ openAhmed K, Kyte D, Keeley T, Efficace F, Armes J, Brown JM, Calman L, Copland C, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M
20162752640610.1016/j.leukres.2016.08.003Pushing the boundaries of care in myelodysplastic syndromes: Physical exercise to improve fatigue and health-related quality of life outcomes.Leukemia researchEfficace F, Cannella L, Cottone F
201627515250A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.HaematologicaChiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, Tedeschi A, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R
20162741657010.2450/2016.0321-15Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.Blood transfusion = Trasfusione del sangueTagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Veneri D, Basso M, Candiotto L, Tassinari C, Federici AB, De Stefano V,
20162735171510.1002/ajh.24463Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.American journal of hematologyEfficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG
20162726001510.1007/s00520-016-3286-zPersonal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerBreccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, Efficace F, Alimena G
20162715199310.3324/haematol.2015.139410RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.HaematologicaGianfelici V, Chiaretti S, Demeyer S, Di Giacomo F, Messina M, La Starza R, Peragine N, Paoloni F, Geerdens E, Pierini V, Elia L, Mancini M, De Propris MS, Apicella V, Gaidano G, Testi AM, Vitale A, Vignetti M, Mecucci C, Guarini A, Cools J, Foà R
20162714266610.1080/03007995.2016.1185399Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?Current medical research and opinionBreccia M, Efficace F
20162713381910.1038/leu.2016.122PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.LeukemiaCicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F
20162705900610.1002/ajh.24379Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic work-up.American journal of hematologyMauro FR, Coluzzi S, Paoloni F, Trastulli F, Armiento D, Ferretti A, Giovannetti G, Colafigli G, Molica M, la Rocca U, De Propris MS, Caronna R, Morano G, Guarini A, Girelli G, Foà R
20162700797010.1056/NEJMc1513710Targeted Therapy Alone for Acute Promyelocytic Leukemia.The New England journal of medicineLo-Coco F, Di Donato L, , Schlenk RF,
20162695430510.1586/17474086.2016.1164030Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models.Expert review of hematologyNiscola P, Mandelli F, Efficace F
20162694447410.3324/haematol.2015.140335Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).HaematologicaAbel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ
20162694303710.18632/oncotarget.7819Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia.OncotargetMarinelli M, Ilari C, Xia Y, Del Giudice I, Cafforio L, Della Starza I, Raponi S, Mariglia P, Bonina S, Yu Z, Yang W, Qiu L, Chan T, Piciocchi A, Kwong YL, Tse E, Li J, Guarini A, Xu W, Foà R
20162691380910.1111/bjh.13991Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.British journal of haematologyGiona F, Moleti ML, De Benedittis D, Santopietro M, Nanni M, Testi AM, Orlando S, Iori AP, Piciocchi A, Gottardi E, Barberi W, Diverio D, Saglio G, Foà R
20162691038810.1002/ajh.24341Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.American journal of hematologyZaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R
20162688618110.1016/j.ejca.2016.01.001Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey.European journal of cancer (Oxford, England : 1990)Gerritsen A, Jacobs M, Henselmans I, van Hattum J, Efficace F, Creemers GJ, de Hingh IH, Koopman M, Molenaar IQ, Wilmink HW, Busch OR, Besselink MG, van Laarhoven HW,
20162688310410.18632/oncotarget.7356Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.OncotargetMessina M, Chiaretti S, Wang J, Fedullo AL, Peragine N, Gianfelici V, Piciocchi A, Brugnoletti F, Di Giacomo F, Pauselli S, Holmes AB, Puzzolo MC, Ceglie G, Apicella V, Mancini M, Te Kronnie G, Testi AM, Vitale A, Vignetti M, Guarini A, Rabadan R, Foà R
20162685140610.1016/j.ejca.2015.12.025Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.European journal of cancer (Oxford, England : 1990)Mercieca-Bebber RL, Perreca A, King M, Macann A, Whale K, Soldati S, Jacobs M, Efficace F
20162681152410.1200/JCO.2015.64.0060Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.Journal of clinical oncology : official journal of the American Society of Clinical OncologyAmadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F
20162675455610.1016/j.leukres.2015.11.018CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.Leukemia researchChiaretti S, Brugnoletti F, Messina M, Paoloni F, Fedullo AL, Piciocchi A, Elia L, Vitale A, Mauro E, Ferrara F, De Fabritiis P, Luppi M, Ronco F, De Propris MS, Raponi S, Kronnie GT, Vignetti M, Guarini A, Foà R
20162668454510.1111/bjh.13870Clinical features and prognostic factors in solitary plasmacytoma.British journal of haematologyFinsinger P, Grammatico S, Chisini M, Piciocchi A, Foà R, Petrucci MT
20162667784610.1007/s11523-015-0409-2Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Targeted oncologySodergren SC, Copson E, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD
20162654635910.1007/s00277-015-2541-6The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Annals of hematologyEfficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, Fava C, Angelucci E, Mandelli F, Baccarani M
20162627597910.1007/s11136-015-1099-zInternational Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationKyte D, Reeve BB, Efficace F, Haywood K, Mercieca-Bebber R, King MT, Norquist JM, Lenderking WR, Snyder C, Ring L, Velikova G, Calvert M
20162623862810.1007/s00520-015-2868-5Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerNiscola P, Siniscalchi A, Tendas A, de Fabritiis P, Caravita T, Efficace F
20162520454110.1136/bmjspcare-2014-000726Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.BMJ supportive & palliative careEfficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E
20152645366010.1182/blood-2015-07-658922Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.BloodEfficace F, Mandelli F, Platzbecker U, Cottone F, Lo Coco F
20152641035210.1007/s00277-015-2486-9Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).Annals of hematologyde Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F
20152640450110.1016/S1470-2045(15)00206-5Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.The Lancet. OncologyEfficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F
20152632446110.1016/j.critrevonc.2015.07.012Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?Critical reviews in oncology/hematologyCannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F
20152628294410.1016/j.leukres.2015.07.004Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.Leukemia researchBreccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G
20152621251610.1111/bjh.13576Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.British journal of haematologySymeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhäuser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kröger N,
20152612010010.1016/j.leukres.2015.05.012Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.Leukemia researchCaocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F
20152611341910.3324/haematol.2015.129221Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.HaematologicaGugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G,
20152595618910.1016/j.urolonc.2015.04.002Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review.Urologic oncologyFeuerstein MA, Jacobs M, Piciocchi A, Bochner B, Pusic A, Fayers P, Blazeby J, Efficace F,
20152591098710.1007/s00432-015-1970-xPatient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making.Journal of cancer research and clinical oncologyRees JR, Whale K, Fish D, Fayers P, Cafaro V, Pusic A, Blazeby JM, Efficace F
20152589119210.1111/bjh.13453Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.British journal of haematologyGiona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, Iaria G, Ladogana S, Burnelli R, Consarino C, Varotto S, Tucci F, Messina C, Nanni M, Diverio D, Biondi A, Pession A, Locatelli F, Piciocchi A, Gottardi E, Saglio G, Foà R
20152586902910.1007/s00277-015-2364-5Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.Annals of hematologyBuccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A
20152586270210.3324/haematol.2015.125484Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement.HaematologicaGirmenia C, Viscoli C, Piciocchi A, Cudillo L, Botti S, Errico A, Sarmati L, Ciceri F, Locatelli F, Giannella M, Bassetti M, Tascini C, Lombardini L, Majolino I, Farina C, Luzzaro F, Rossolini GM, Rambaldi A
20152582429310.1159/000370023Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.Acta haematologicaBeksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A
20152569168010.1200/JCO.2014.60.3597Reply to M. Koehler et al.Journal of clinical oncology : official journal of the American Society of Clinical OncologyEfficace F, Cottone F, Lo-Coco F
20152565009110.1038/leu.2015.21Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.LeukemiaMauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R
20152564276410.1038/bmt.2014.322Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.Bone marrow transplantationBrioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M
20152543062510.1111/bjh.13250Managing children with chronic myeloid leukaemia.British journal of haematologyBaccarani M
20152540241810.1038/bmt.2014.262High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.Bone marrow transplantationHengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T
20152536199510.1093/annonc/mdu490Differences among young adults, adults and elderly chronic myeloid leukemia patients.Annals of oncology : official journal of the European Society for Medical OncologyCastagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G,
20152531030210.1038/bmt.2014.231Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy.Bone marrow transplantationGirmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, Scimè R, Lombardini L, Viscoli C, Rambaldi A, ,
20152527233210.1111/bjh.13138Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.British journal of haematologyEfficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F
20152509663610.1007/s00277-014-2177-ySpecific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.Annals of hematologyOosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T
20152502751510.1038/leu.2014.219Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.LeukemiaFerrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Falcone AP, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A
20142524544610.1200/JCO.2014.55.3453Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.Journal of clinical oncology : official journal of the American Society of Clinical OncologyEfficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F
20142523205910.1182/blood-2014-06-583021Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.BloodBarcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A
20142515931310.1002/ajh.23835Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.American journal of hematologyTacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M
20142503465610.1016/j.ejca.2014.06.016The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review.European journal of cancer (Oxford, England : 1990)Dirven L, Taphoorn MJ, Reijneveld JC, Blazeby J, Jacobs M, Pusic A, La Sala E, Stupp R, Fayers P, Efficace F,
20142501593810.3324/haematol.2014.103853Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.HaematologicaCaltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, Bringhen S, Musolino C, Baldini L, Musto P, Petrucci MT, Gaidano G, Passera R, Bruno B, Palumbo A, Boccadoro M, Omedè P
20142499460610.1007/s00277-014-2055-7Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.Annals of hematologyAslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH
20142498668910.1182/blood-2013-08-518514Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.BloodKroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, Boezeman JB, Marie JP, Halkes CJ, de Witte T, Huls G, Suciu S, Wevers RA, van der Reijden BA, Jansen JH,
20142490276710.1186/1477-7525-12-86Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry.Health and quality of life outcomesEfficace F, Rees J, Fayers P, Pusic A, Taphoorn M, Greimel E, Reijneveld J, Whale K, Blazeby J,
20142488880610.1200/JCO.2013.53.0329Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.Journal of clinical oncology : official journal of the American Society of Clinical OncologyMoreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY
20142482511410.1016/j.ejca.2014.04.005Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making.European journal of cancer (Oxford, England : 1990)Efficace F, Jacobs M, Pusic A, Greimel E, Piciocchi A, Kieffer JM, Gilbert A, Fayers P, Blazeby J,
20142482093210.1016/j.ejca.2014.04.018Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities.European journal of cancer (Oxford, England : 1990)van Leeuwen M, Efficace F, Fosså SD, Bolla M, De Giorgi U, de Wit R, Holzner B, van de Poll-Franse LV, van Poppel H, White J, Collette L, Osanto S, Aaronson NK, , ,
20142481391810.1038/leu.2014.155Circulating miRNA markers show promise as new prognosticators for multiple myeloma.LeukemiaRocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F
20142476340210.3324/haematol.2013.099341Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.HaematologicaMateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A
20142470218610.1111/ejh.12337Patient-reported outcomes in acute leukemia: a roadmap for future research.European journal of haematologyEfficace F, Breccia M, Lo Coco F
20142468242110.1007/s00277-014-2056-6Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).Annals of hematologyWillemze R, Suciu S, Muus P, Halkes CJ, Meloni G, Meert L, Karrasch M, Rapion J, Vignetti M, Amadori S, de Witte T, Marie JP
20142463173810.1016/j.bbmt.2014.03.004Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGirmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, Pecoraro C, Guidi S, Iori AP, Montante B, Chiusolo P, Lanino E, Carella AM, Zucchetti E, Bruno B, Irrera G, Patriarca F, Baronciani D, Musso M, Prete A, Risitano AM, Russo D, Mordini N, Pastore D, Vacca A, Onida F, Falcioni S, Pisapia G, Milone G, Vallisa D, Olivieri A, Bonini A, Castagnola E, Sica S, Majolino I, Bosi A, Busca A, Arcese W, Bandini G, Bacigalupo A, Rambaldi A, Locasciulli A
20142459798410.3109/10428194.2014.898760NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.Leukemia & lymphomaChiaretti S, Marinelli M, Del Giudice I, Bonina S, Piciocchi A, Messina M, Vignetti M, Rossi D, Di Maio V, Mauro FR, Guarini A, Gaidano G, Foà R
20142458278310.1016/j.bbmt.2014.02.018Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGirmenia C, Barosi G, Piciocchi A, Arcese W, Aversa F, Bacigalupo A, Bandini G, Bosi A, Busca A, Castagnola E, Caselli D, Cesaro S, Ciceri F, Locasciulli A, Locatelli F, Mikulska M, Pagano L, Prete A, Raiola AM, Rambaldi A
20142458014710.1111/ejh.12300Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).European journal of haematologyAngelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S
20142453456910.1016/j.leukres.2014.01.007Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia.Leukemia researchGirmenia C, Micozzi A, Piciocchi A, Gentile G, Di Caprio L, Nasso D, Minotti C, Capria S, Cartoni C, Alimena G, Meloni G, Amadori S, Foà R, Venditti A
20142449755710.3324/haematol.2013.094045Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.HaematologicaBaccarani M, Efficace F, Rosti G
20142449594210.1016/j.critrevonc.2014.01.002Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.Critical reviews in oncology/hematologySodergren SC, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD
20142447832110.1093/annonc/mdt557Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.Annals of oncology : official journal of the European Society for Medical OncologyEfficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F
20142445511910.4084/MJHID.2014.010A critical history of chromic myeloid leukemia.Mediterranean journal of hematology and infectious diseasesBaccarani M, Pane F
20142431458910.1016/j.leukres.2013.11.009Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.Leukemia researchMauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R,
20142429794010.1200/JCO.2013.51.8571High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.Journal of clinical oncology : official journal of the American Society of Clinical OncologyWillemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T
20142424148810.3324/haematol.2013.093724Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.HaematologicaEfficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S, Vignetti M, Mandelli F, Baccarani M
20142422027410.1038/leu.2013.334Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.LeukemiaCortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R
20142421009110.1016/j.eururo.2013.10.017Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making.European urologyEfficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A, Blazeby J,
20142402663410.1007/s11136-013-0523-5International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationEfficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F
20142390662510.1016/j.leukres.2013.07.003Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.Leukemia researchEfficace F, Rosti G, Cottone F, Breccia M, Castagnetti F, Iurlo A, Mandelli F, Baccarani M
20132416868010.1186/1477-7525-11-184The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice.Health and quality of life outcomesCalvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F
20132412744210.1200/JCO.2013.49.0771Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).Journal of clinical oncology : official journal of the American Society of Clinical OncologyAmadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lübbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP
20132389796110.1200/JCO.2012.48.4626Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.Journal of clinical oncology : official journal of the American Society of Clinical OncologySonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P
20132374080310.1002/sim.5868The added value of propensity score matching when using health-related quality of life reference data.Statistics in medicineCottone F, Efficace F, Apolone G, Collins GS
20132371653910.3324/haematol.2012.080432Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.HaematologicaChiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foà R
20132341702910.1038/leu.2013.51Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.LeukemiaEfficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F
20132317779710.1016/j.leukres.2012.10.021Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.Leukemia researchEfficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F
20122298535310.1111/ejh.12004Predicting survival in advanced hematologic malignancies: do patient-reported symptoms matter?European journal of haematologyEfficace F, Cartoni C, Niscola P, Tendas A, Meloni E, Scaramucci L, Soldati S, Brunetti GA, Marini MG, Mandelli F
20122287188410.1038/bjc.2012.348Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.British journal of cancerEfficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F
20122278673010.1002/cncr.27657Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.CancerRago A, Grammatico S, Za T, Levi A, Mecarocci S, Siniscalchi A, De Rosa L, Felici S, Bongarzoni V, Piccioni AL, La Verde G, Pisani F, Franceschini L, Paviglianiti AL, Caravita T, Petrucci MT, De Stefano V, Cimino G,
201222692507Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.BloodLuatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N,
20122254382610.1007/s00277-012-1458-6Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.Annals of hematologyEfficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F, Sprangers M
20122246094710.1007/s00277-012-1436-zIntensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.Annals of hematologyHengeveld M, Suciu S, Karrasch M, Specchia G, Marie JP, Muus P, Petti MC, Rotoli B, Amadori S, Fioritoni G, Leoni P, Morra E, Thaler J, Resegotti L, Fazi P, Vignetti M, Mandelli F, Zittoun R, de Witte T
20122238108210.1186/1756-9966-31-17IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.Journal of experimental & clinical cancer research : CRPisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, De Stefano V, La Verde G, Gentilini F, Levi A, Za T, Moscetti A, Annino L, Petti MC,
20122236741110.1007/s11060-012-0819-2Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies.Journal of neuro-oncologyEfficace F, Taphoorn M
20122208231410.1111/j.1365-2141.2011.08940.xTemsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).British journal of haematologyAmadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E, Di Raimondo F, Fozza C, Annino L, Chiarini F, Ricci F, Ammatuna E, La Sala E, Fazi P, Vignetti M
20122204951810.1182/blood-2011-07-369595Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols.BloodBreccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G, Testi AM, Avvisati G, Petti MC, Minotti C, Latagliata R, Foà R, Pelicci PG, Lo-Coco F
20122203908910.1093/annonc/mdr480Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.Annals of oncology : official journal of the European Society for Medical OncologyD'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A, Ferrara F, Palumbo A, Pagano L, Musto P
20122193238610.1002/cncr.26447Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.CancerGozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Patriarca F, Nozzoli C, Cavo M, Offidani M, Floridia M, Berretta S, Vallone R, Musto P, Lauria F, , Marchini E, Fabbri A, Oliva S, Zamagni E, Sapienza FG, Ballanti S, Mele G, Galli M, Pirrotta MT, Di Raimondo F
20122143589910.1016/j.critrevonc.2011.02.007Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes.Critical reviews in oncology/hematologyEfficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, Baccarani M, Mandelli F,
201122215391[Results of treatment of acute lymphoblastic leukemia in two cohorts of Mexican patients].Revista medica de ChileRamos C, Rozen E, León M, Martínez T A, Olarte I, Catellanos H, Martínez C, Montaño E, Kassack I J, Zamora J, Miranda E, De la Ros A, Gutiérrez M, Collazo J
20112208466810.1155/2011/794240The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.ThrombosisMarchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T
20112205327810.4081/pr.2011.s2.e2Acute lymphoblastic leukemia: age and biology.Pediatric reportsFoà R
20112195361710.1002/ajh.22171The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.American journal of hematologyLaurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D'Arena G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, Tedeschi A, Ambrosetti A, Gaidano G, Leone G, Foà R
20112193111310.1182/blood-2011-05-351403Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.BloodFoà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M,
20112191530410.1371/journal.pone.0024265Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization.PloS oneJager E, van der Velden VH, te Marvelde JG, Walter RB, Agur Z, Vainstein V
20112175198410.1111/j.1365-2141.2011.08593.xGIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.British journal of haematologyLatagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F,
20112175031310.1182/blood-2011-04-347575Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.BloodEfficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F,
20112145090010.1182/blood-2010-12-324228Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.BloodGugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G,
20112144783410.1182/blood-2011-01-328294Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.BloodMarzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, Testoni N,
20112097182110.3324/haematol.2010.030189Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group.HaematologicaMolica S, Mauro FR, Giannarelli D, Lauria F, Cortelezzi A, Brugiatelli M, Liso V, Cuneo A, Foà R
201020944181Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission.Anticancer researchFerrara F, Finizio O, Izzo T, Riccardi C, Criscuolo C, Carbone A, Borlenghi E, Rossi G
20102064412110.1182/blood-2010-03-276196Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.BloodLo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F,
20102053469910.3324/haematol.2009.020792The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.HaematologicaIacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT, Vignetti M, Cilloni D, Messa F, Guadagnuolo V, Paolini S, Elia L, Messina M, Vitale A, Meloni G, Soverini S, Pane F, Baccarani M, Foà R, Martinelli G
20102050976910.3109/10428194.2010.487959Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Leukemia & lymphomaEngelhardt M, Kleber M, Udi J, Wäsch R, Spencer A, Patriarca F, Knop S, Bruno B, Gramatzki M, Morabito F, Kropff M, Neri A, Sezer O, Hajek R, Bunjes D, Boccadoro M, Straka C, Cavo M, Polliack A, Einsele H, Palumbo A
20102043963510.1200/JCO.2009.26.7963Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.Journal of clinical oncology : official journal of the American Society of Clinical OncologyCastagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G
201020393021Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients.Anticancer researchFerrara F, Finizio O, D'Arco A, Mastrullo L, Cantore N, Musto P
20102023040510.1111/j.1365-2141.2010.08095.xRandomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).British journal of haematologyAmadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, Rizzoli V, Borlenghi E, Gaidano G, Magro D, Torelli G, Muus P, Venditti A, Cacciola E, Lauria F, Vignetti M, de Witte T
20102010715410.3324/haematol.2009.009035The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience.HaematologicaCimino G, Cenfra N, Elia L, Sica S, Luppi M, Meloni G, Vignetti M, Paoloni F, Foà R, Mandelli F
20102006755910.1111/j.1365-2141.2009.08056.xRescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study.British journal of haematologyMatteucci C, Barba G, Varasano E, Vitale A, Mancini M, Testoni N, Cuneo A, Rege-Cambrin G, Elia L, La Starza R, Pierini V, Brandimarte L, Vignetti M, Foà R, Mecucci C,
20101993044110.1111/j.1600-0609.2009.01385.xSafety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.European journal of haematologyMorabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M
20101990367310.3324/haematol.2009.011767The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.HaematologicaMolica S, Mauro FR, Callea V, Giannarelli D, Lauria F, Rotoli B, Cortelezzi A, Liso V, Foà R
20091982613210.1200/JCO.2008.20.6490Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.Journal of clinical oncology : official journal of the American Society of Clinical OncologyMandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T
20091979751810.1182/blood-2009-07-229864Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.BloodTestoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinelli G, Pane F, Rosti G, Baccarani M
20091977038110.1200/JCO.2008.21.6408IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.Journal of clinical oncology : official journal of the American Society of Clinical OncologyMartinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foà R
200919663768First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.Current drug targetsMusto P, D'Auria F, Pietrantuono G, Baldini L, Bringhen S, Caravita T, Di Raimondo F, Morabito F, Offidani M, Petrucci MT, Tosi P, Gay F, Cavo M, Boccadoro M, Palumbo A
20091958992610.1182/blood-2008-08-173963Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).BloodIacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, Martinelli G
20091953996110.1016/j.medcli.2008.09.046[B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA pronostic indexes].Medicina clinicaGonzález Rodríguez AP, González García E, Fernández Alvarez C, González Huerta AJ, González Rodríguez S
20091921193810.1182/blood-2007-08-103499Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.BloodCastagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G,
20091914465610.3324/haematol.13529The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.HaematologicaPalandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G
20081895045810.1111/j.1365-2141.2008.07400.xLiposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.British journal of haematologyLatagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F
20081855568210.1016/j.ejca.2008.03.017Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making.European journal of cancer (Oxford, England : 1990)Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B
20081850880110.3324/haematol.11889M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.HaematologicaPulsoni A, Iacobelli S, Bernardi M, Borgia M, Camera A, Cantore N, Di Raimondo F, Fazi P, Ferrara F, Leoni F, Liso V, Mancini M, Marmont F, Matturro A, Maurillo L, Melillo L, Meloni G, Mirto S, Specchia G, Valentini CG, Venditti A, Leone G, Foà R, Mandelli F, Pagano L
20081850879910.3324/haematol.12004Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.HaematologicaLo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G,
20081842105510.1200/JCO.2007.12.3117Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.Journal of clinical oncology : official journal of the American Society of Clinical OncologyEfficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F,
20081827106410.1002/hon.846Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.Hematological oncologyFerrara F, Fazi P, Venditti A, Pagano L, Amadori S, Mandelli F
20081816564410.1200/JCO.2007.13.2373Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.Journal of clinical oncology : official journal of the American Society of Clinical OncologyPalandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M,
200717785703Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.Journal of clinical oncology : official journal of the American Society of Clinical OncologyPalumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT,
200717351113ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.BloodGregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M, Milella M, Foà R, Tafuri A,
200717339189Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.HaematologicaThomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S
200717339183Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.HaematologicaVitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R
200717229641Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.HaematologicaRosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G
200717213285Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.BloodVignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foà R, Baccarani M, Mandelli F
200717135723Late relapses in acute promyelocytic leukaemia.Acta haematologicaLatagliata R, Carmosino I, Breccia M, Minni A, Testi A, Iorio N, Lo-Coco F, Avvisati G, Petti MC, Mandelli F, Cimino G
200717077333Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.BloodMazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F,
20061863249610.3816/SCT.2006.n.018Role of prophylactic antibiotics in the prevention of infections after chemotherapy: a literature review.Supportive cancer therapyMoon S, Williams S, Cullen M
200617189410Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer ResearchSoverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G,
200617145607Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia.HaematologicaBarcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, Cortelezzi A, Laurenti L, Pogliani EM, Pedotti P, Liso V, Girelli G, Mandelli F, Zanella A,
200616977651Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.CancerLeibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV
200616932345Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.LeukemiaJehn U, Suciu S, Thomas X, Lefrère F, Muus P, Berneman Z, Marie JP, Adamo F, Fillet G, Nobile F, Ricciuti F, Leone G, Rizzoli V, Montanaro M, Beeldens F, Fazi P, Mandelli F, Willemze R, de Witte T, Amadori S
200616720834Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.BloodFalini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, Diverio D, Nicoletti I, Pacini R, Tabarrini A, Galletti BV, Mannucci R, Roti G, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo-Coco F, Saglio G, Pelicci PG, Martelli MF, Mecucci C
200616619048Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia.LeukemiaTrubia M, Albano F, Cavazzini F, Cambrin GR, Quarta G, Fabbiano F, Ciambelli F, Magro D, Hernandezo JM, Mancini M, Diverio D, Pelicci PG, Coco FL, Mecucci C, Specchia G, Rocchi M, Liso V, Castoldi G, Cuneo A
200616531262The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.HaematologicaCimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, Meloni G, Mancini M, Tedeschi A, Di Raimondo F, Specchia G, Fioritoni G, Leoni P, Cuneo A, Mecucci C, Saglio G, Mandelli F, Foà R,
200616179376Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol.BloodVitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R
200516243790Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation.Clinical cancer research : an official journal of the American Association for Cancer ResearchChiaretti S, Li X, Gentleman R, Vitale A, Wang KS, Mandelli F, Foà R, Ritz J
200516032778A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia.Leukemia & lymphomaMolica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, Lauria F, Rotoli B, Montanaro M, Cortelezzi A, Liso V, Mandelli F, Foa R,
200516019523The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.Leukemia & lymphomaFassas A, Anagnostopoulos A
200515867198ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical OncologySoverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M
200515677559GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.BloodTesti AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, Menna G, Locatelli F, Pession A, Barisone E, De Rossi G, Diverio D, Micalizzi C, Aricò M, Basso G, Foa R, Mandelli F
200515668275Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials.Annals of oncology : official journal of the European Society for Medical OncologyPagano L, Pulsoni A, Vignetti M, Tosti ME, Falcucci P, Fazi P, Fianchi L, Levis A, Bosi A, Angelucci E, Bregni M, Gabbas A, Peta A, Coser P, Ricciuti F, Morselli M, Caira M, Foà R, Amadori S, Mandelli F, Leone G,
200515650057A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.BloodMancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, Tedeschi A, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R
200515621806Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).Leukemia & lymphomaOffidani M, Corvatta L, Malerba L, Marconi M, Catarini M, Centurioni R, Leoni F, Scortechini AR, Masia MC, Leoni P
200415580686Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004.Blood cells, molecules & diseasesAversa F, Berneman ZN, Locatelli F, Martelli MF, Reisner Y, Tabilio A, Velardi A, Vuk-Pavlovic S
200415339678Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.HaematologicaAmadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R, Ho A, Denzlinger C, Leone G, Fabris P, Muus P, Vignetti M, Hagemeijer A, Beeldens F, Anak O, De Witte T, ,
200415257938Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.HaematologicaPagano L, Fianchi L, Caramatti C, D'Antonio D, Melillo L, Caira M, Masini L, Todeschini G, Girmenia C, Martino B, Cinieri S, Martino P, Del Favero A,
200415124706Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia.Annals of hematologyWillemze R, Suciu S, Mandelli F, de Witte T, Amador S,
200415020267Survival of elderly patients with acute myeloid leukemia.HaematologicaPulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, De Paoli L, Di Bona E, Invernizzi R, Marmont F, Petti MC, Rigolin G, Ronco F, Spadano A, Tosti ME, Visani G, Mele A, Mandelli F
200415003889GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia.HaematologicaCamera A, Annino L, Chiurazzi F, Fazi P, Cascavilla N, Fabbiano F, Marmont F, Di Raimondo F, Recchia A, Vignetti M, Rotoli B, Mandelli F
200414749702Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials.LeukemiaPagano L, Pulsoni A, Tosti ME, Caramatti C, Cerri R, Falcucci P, Fazi P, Fianchi L, Martino B, Mattei D, Offidani M, Pacilli L, Pogliani EM, Rotoli B, Specchia G, Visani G, Vignetti M, Voso MT, Leone G, Mandelli F,
200314576731Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.LeukemiaVenditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del Principe MI, Consalvo MI, De Fabritiis P, Cudillo L, Picardi A, Franchi A, Lo-Coco F, Amadori S
200312810259Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature.Cancer genetics and cytogeneticsSpirito FR, Mancini M, Derme V, Cimino G, Testi AM, Tafuri A, Vitale A, Foà R
200312801292Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.European journal of haematologyCandoni A, Damiani D, Michelutti A, Masolini P, Michieli M, Michelutti T, Geromin A, Fanin R
200312791662Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome.BloodCimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, Vitale A, Specchia G, Di Raimondo F, Recchia A, Cuneo A, Mecucci C, Pane F, Saglio G, Foa R, Mandelli F,
200312764372Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.LeukemiaMandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, Gobbi M, Nobile F, Gallo E, Fanin R, Amadori S, Vignetti M, Fioritoni G, Ferrara F, Peta A, Giustolisi R, Broccia G, Petti MC, Lo-Coco F,
200312750698The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).LeukemiaOosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Zittoun R, Hess U, Anak O, Beeldens F, Willemze R, de Witte T
200312714526Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.BloodSuciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R,
200312713812Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome.DNA repairCasorelli I, Offman J, Mele L, Pagano L, Sica S, D'Errico M, Giannini G, Leone G, Bignami M, Karran P
200312707726FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.Annals of hematologyPastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V
200312580965E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features.British journal of haematologyFoa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, Lombardo R, Saglio G, Torelli G, Annino L, Specchia G, Damasio E, Recchia A, Di Raimondo F, Morra E, Volpe E, Tafuri A, Fazi P, Hunger SP, Mandelli F
200312529661The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial.LeukemiaKeating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R, ,
200312492579Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia.British journal of haematologyKrampera M, Vitale A, Vincenzi C, Perbellini O, Guarini A, Annino L, Todeschini G, Camera A, Fabbiano F, Fioritoni G, Nobile F, Szydlo R, Mandelli F, Foà R, Pizzolo G
200212391538Acute lymphoblastic leukemia in the elderly.The hematology journal : the official journal of the European Haematology AssociationAnnino L, Goekbuget N, Delannoy A
200212384411Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.BloodAvvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F,
200212357357Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia.LeukemiaMancini M, Vegna ML, Castoldi GL, Mecucci C, Spirito F, Elia L, Tafuri A, Annino L, Pane F, Rege-Cambrin G, Gottardi M, Leoni P, Gallo E, Camera A, Luciano L, Specchia G, Torelli G, Sborgia M, Gabbas A, Tedeschi A, Della Starza I, Cascavilla N, Di Raimondo F, Mandelli F, Foà R
200212200673Acute megakaryoblastic leukemia: experience of GIMEMA trials.LeukemiaPagano L, Pulsoni A, Vignetti M, Mele L, Fianchi L, Petti MC, Mirto S, Falcucci P, Fazi P, Broccia G, Specchia G, Di Raimondo F, Pacilli L, Leoni P, Ladogana S, Gallo E, Venditti A, Avanzi G, Camera A, Liso V, Leone G, Mandelli F,
200212200354Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.BloodPulsoni A, Pagano L, Lo Coco F, Avvisati G, Mele L, Di Bona E, Invernizzi R, Leoni F, Marmont F, Mele A, Melillo L, Nosari AM, Pogliani EM, Vignetti M, Visani G, Zagonel V, Leone G, Mandelli F
200212184278Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Gruppo Italiano Malattie Ematologiche dell'Adulto.BloodPagano L, Pulsoni A
200212130511MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.BloodTafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, Tedeschi A, Fioritoni G, Ferrara F, Di Raimondo F, Gallo E, Liso V, Fabbiano F, Cascavilla N, Pizzolo G, Camera A, Pane F, Lanza F, Cilloni D, Annino L, Vitale A, Vegna ML, Vignetti M, Foà R, Mandelli F,
200211972521Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.British journal of haematologyPagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini G, Cappucci MA, Russo D, Corvatta L, Martino P, Del Favero A
200211890999Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation.Cancer genetics and cytogeneticsScaravaglio P, Guglielmelli T, Giugliano E, Marmont F, Audisio E, Gallo E, Saglio G, Rege-Cambrin G
200211806988Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.BloodAnnino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F,
200111522544Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program.HaematologicaPagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, Buelli M, Picardi M, Allione B, Corvatta L, D'Antonio D, Montillo M, Melillo L, Chierichini A, Cenacchi A, Tonso A, Cudillo L, Candoni A, Savignano C, Bonini A, Martino P, Del Favero A, ,
200111484970Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.Journal of experimental & clinical cancer research : CRClavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, Canepa L, Miglino M, Muner P, Damasio E, Gobbi M
200111300325Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group.Annals of oncology : official journal of the European Society for Medical OncologyPagano L, Pulsoni A, Mele L, Tosti ME, Cerri R, Visani G, Melillo L, Candoni A, Clavio M, Nosari A, Petti MC, Martino B, Mele A, Levis A, Allione B, Almici C, Equitani F, Leone G, Mandelli F,
200111225603Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia.British journal of haematologyPagana L, Pulsoni A, Tosti ME, Avvisati G, Mele L, Mele M, Martino B, Visani G, Cerri R, Di Bona E, Invernizzi R, Nosari A, Clavio M, Allione B, Coser P, Candoni A, Levis A, Camera A, Melillo L, Leone G, Mandelli F,
200011920210Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have common risk factors?The hematology journal : the official journal of the European Haematology AssociationPagano L, Pulsoni A, Tosti ME, Mele A, Mele L, Corvatta L, Miraglia E, Almici C, Manna A, Del Poeta G, Lanza F, Masini L, Recchia A, Equitani F, Leone G, Mandelli F,
200011187562Is workflow technology suitable to represent and manage clinical trials?Studies in health technology and informaticsFazi P, Grifoni P, Luzi D, Ricci FL, Vignetti M
200011091221Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto.British journal of haematologyMontillo M, Tedeschi A, Pagano L, Venditti A, Ferrara F, Fabris P, Martino B, Musso M, De Rosa G, Specchia G, Monaco M, Sparaventi G, Spadea A, Palmas A, Deplano W, Manna A, Melillo L, Miraglia E, Mirto S, Mandelli F
200011091211The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme.British journal of haematologyGirmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P
200010965736[Retinoic acid syndrome. Severe respiratory insufficiency treated with CPAP].Minerva anestesiologicaTommasino C, De Felice L, Colombo S, Salaris D, Capocasa T, Giudici D
200010942364Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.BloodSanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F
200010929031t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia.British journal of haematologyMecucci C, La Starza R, Negrini M, Sabbioni S, Crescenzi B, Leoni P, Di Raimondo F, Krampera M, Cimino G, Tafuri A, Cuneo A, Vitale A, Foà R
200010792270Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.British journal of haematologyDi Bona E, Avvisati G, Castaman G, Luce Vegna M, De Sanctis V, Rodeghiero F, Mandelli F
200010721774Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases.Leukemia & lymphomaCascavilla N, Melillo L, D'Arena G, Greco MM, Carella AM, Sajeva MR, Perla G, Matera R, Minervini MM, Carotenuto M
199910673975Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA).European journal of cancer (Oxford, England : 1990)Keating S, de Witte T, Suciu S, Mandelli F, Damasio E, Willemze R, Morra E, Amadori S, Dardenne M, Vegna ML, Zittoun RA
199910520009Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.British journal of haematologyPagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, Martino B, Guglielmi C, Cerri R, Di Bona E, Invernizzi R, Castagnola C, Bassan R, Mele L, Todeschini G, Leone G, Mandelli F
199910509043The incidence of secondary leukemias.HaematologicaLeone G, Mele L, Pulsoni A, Equitani F, Pagano L
199910477455Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.HaematologicaGirmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, Spadea A, Tosti S, Mecarocci S, D'Elia GM, Tafuri A, Cimino G, Mandelli F
199910456442Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia. A phase III, randomized, multicenter study. GIMEMA. Gruppo Italiano per le Malattie Ematologiche dell'Adulto. GITMO-Gruppo Italiano Trapianto di Midollo Osseo.Hematology and cell therapy
199910362124Human herpes virus-6 seroprevalence and leukaemias: a case-control study. GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto).British journal of cancerGentile G, Mele A, Ragona G, Faggioni A, Zompetta C, Tosti ME, Visani G, Castelli G, Pulsoni A, Monarca B, Martino P, Mandelli F
199910064240Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaMenichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagańo L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F
199810037004Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.Leukemia & lymphomaGiona F, Annino L, Testi AM, Rondelli R, Arcese W, Meloni G, Moleti ML, Mandelli F
19989864917Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.HaematologicaMartinelli G, Ottaviani E, Testoni N, Visani G, Diverio D, D'Elia G, Mandelli F, Tura S
19989855248Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative Group.European journal of haematologyPulsoni A, Stazi A, Cotichini R, Allione B, Cerri R, Di Bona E, Nosari AM, Pagano L, Recchia A, Ribersani M, Rocchi L, Veneri D, Visani G, Mandelli F, Mele A
19989753069The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.British journal of haematologyKeating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, Resegotti L, Ferrini PR, Caronia F, Dardenne M, Solbu G, Petti MC, Vegna ML, Mandelli F, Zittoun RA
19989680345Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.BloodDiverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F
19989531332Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.British journal of haematologyPagano L, Annino L, Ferrari A, Camera A, Martino B, Montillo M, Tosti ME, Mele A, Pulsoni A, Vegna ML, Leone G, Mandelli F
19979457393Interleukin-2 therapy in relapsed acute myelogenous leukemia.The cancer journal from Scientific AmericanMeloni G, Vignetti M, Pogliani E, Invernizzi R, Allione B, Mirto S, Sica S, Leoni F, Selleri C, Mandelli F
19979375750Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).British journal of haematologyPagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, Cenacchi A, Pacilli L, Fabbiano F, Del Favero A
19979313879Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.Bone marrow transplantationCarlo-Stella C, Tabilio A, Regazzi E, Garau D, La Tagliata R, Trasarti S, Andrizzi C, Vignetti M, Meloni G
19979285546Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial.Bone marrow transplantationZittoun R, Suciu S, Watson M, Solbu G, Muus P, Mandelli F, Stryckmans P, Peetermans M, Thaler J, Resegotti L, Dardenne M, Willemze R
19979242531Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.BloodMandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F
19979217194Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.British journal of haematologyGiona F, Annino L, Rondelli R, Arcese W, Meloni G, Testi AM, Moleti ML, Amadori S, Resegotti L, Tabilio A, Ladogana S, Fioritoni G, Camera A, Liso V, Leoni P, Mandelli F
19979350178New strategies for the treatment of acute promyelocytic leukaemia.Journal of internal medicine. SupplementMandelli F
19968751460Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.LeukemiaLiso V, Iacopino P, Avvisati G, Petti MC, Broccia G, Carotenuto M, Falda M, Fazi P, Lazzarino M, Leoni P, Mirto S, Pucci G, Nobile F, Nosari AM, Specchia G, Stasi R, Tabilio A, Mandelli F
19968695858AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.BloodAvvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F
19968858693Empirical treatment of fever in neutropenic children: the role of the carbapenems. International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer and the Gimema Infection Program.The Pediatric infectious disease journalCometta A, Viscoli C, Castagnola E, Massimo L, Giacchino R, Gibson B, Giacchino M, Balbo L, Engelhard D, Shapiro M, Amsallem D, Estavoyer JM, Ferster A, Glauser MP
19968974788The EORTC trials for acute myelogenous leukemia. EORTC Leukemia Cooperative Group. European Organisation of Research and Treatment of Cancer.Hematology and cell therapyZittoun R
19968807105Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.Bone marrow transplantationKeating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, Broccia G, Thaler J, Labar B, Damasio E, Bizzi B, Rotoli B, Vekhoff A, Muus P, Petti MC, Dardenne M, Solbu G, Vegna ML, Zittoun RA
19968616033The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy.British journal of haematologyMandelli F, Annino L, Rotoli B
19968901362A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationWatson M, Zittoun R, Hall E, Solbu G, Wheatley K
19957734347Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto).British journal of haematologyPagano L, Ricci P, Nosari A, Tonso A, Buelli M, Montillo M, Cudillo L, Cenacchi A, Savignana C, Melillo L
19957808487Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.The New England journal of medicineZittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G
19957496348Proceedings of the 3rd GIMEMA Conference on Recent Advances in the Cytobiology of Acute Leukemias. Bari, Italy, 13-14 May 1994.Leukemia & lymphoma
19947811016Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.Antimicrobial agents and chemotherapyMenichetti F, Martino P, Bucaneve G, Gentile G, D'Antonio D, Liso V, Ricci P, Nosari AM, Buelli M, Carotenuto M
19947514043Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosisMazzucconi MG, Gugliotta L, Leone G, Dragoni F, Belmonte MM, De Stefano V, Chistolini A, Tura S, Mandelli F
19948075572EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML).Leukemia & lymphomaZittoun R, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Ferrini PR, Visani G, Caronia F, Stryckmans P
19948011548Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica.British journal of haematologyGiona F, Testi AM, Annino L, Amadori S, Arcese W, Camera A, Di Montezemolo LC, Ladogana S, Liso V, Meloni G
19947815837Treatment of patients with acute promyelocytic leukemia. The EORTC-LCG experience. EORTC Leukemia Cooperative Group.LeukemiaWillemze R, Suciu S, Mandelli F, de Witte T, Cadiou M, Castoldi GL, Liso V, Dardenne M, Solbu G, Zittoun R
19938485204Reproducibility of the morphological diagnostic criteria for acute myeloid leukemia: the GIMEMA group experience.Annals of hematologyCastoldi GL, Liso V, Fenu S, Vegna ML, Mandelli F
19938471981Immunophenotype of acute lymphoblastic leukemia cells: the experience of the Italian Cooperative Group (Gimema).Leukemia & lymphomaDe Rossi G, Grossi C, Foà R, Tabilio A, Vègna L, Lo Coco F, Annino L, Camera A, Cascavilla N, Ciolli S
19938426473Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.LeukemiaCarella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L
19938446931Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.Thrombosis and haemostasisLeone G, Gugliotta L, Mazzucconi MG, De Stefano V, Belmonte MM, Dragoni F, Specchia G, Centra A, Gamba G, Camera A
19938427721The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.European journal of cancer (Oxford, England : 1990)Del Favero A, Menichetti F
19921397242Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.European journal of haematologyGugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, Mandelli F
19921317727Identification of DNA rearrangements at the retinoic acid receptor-alpha (RAR-alpha) locus in all patients with acute promyelocytic leukemia (APL) and mapping of APL breakpoints within the RAR-alpha second intron. Italian Cooperative Study Group "GIMEMA".BloodDiverio D, Lo Coco F, D'Adamo F, Biondi A, Fagioli M, Grignani F, Rambaldi A, Rossi V, Avvisati G, Petti MC
19921581404A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.Annals of hematologyMandelli F, Vegna ML, Avvisati G, Amadori S, Spadea A, Cacciola E, Cantore N, De Laurenzi A, De Rosa C, Fioritoni G
19921578949Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.LeukemiaZittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC
19921578948Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.LeukemiaResegotti L
19921578928GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results.LeukemiaMandelli F, Annino L, Vegna ML, Camera A, Ciolli S, Deplano W, Fabiano F, Ferrara F, Ladogana S, Muti G
19921578909Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.LeukemiaZittoun R, Mandelli F, Willemze R, de Witte T, Tura S, Ferrini PR, Stryckmans P, Gattringer C, Petti MC, Solbu G
19911681308Detection of Ph1-positive acute lymphoblastic leukaemia by PCR. GIMEMA Cooperative Study Group.Lancet (London, England)Saglio G, Guerrasio A, Rosso C, Lo Coco F, Frontani M, Annino L, Mandelli F
19912048868Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.Annals of internal medicine
19911780745Allogeneic or autologous bone marrow transplantation for intensification of salvage therapy in patients with high-risk advanced acute lymphoblastic leukemia. The AIEOP/GIMEMA Groups.Seminars in hematologyArcese W, Amadori S, Meloni G, Giona F, Vegna ML, Testi AM, Annino L, Carotenuto M, Resegotti L, Madon E
19911878707Methodology of evaluation in EORTC trials including BMT in acute myelogenous leukemia (AML) in first complete remission (CR). EORTC Leukemia Cooperative Group (LCG) and GIMEMA.Bone marrow transplantationSuciu S, Solbu G, Zittoun R, Hayat M, Willemze R, de Witte T, Mandelli F
19911829918A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.European journal of cancer (Oxford, England : 1990)Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, Falconi E, Geraci E, Ladogana S, Latagliata R
19902098299Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.HaematologicaCastaman G, Rodeghiero F, Dini E
19902202470Relative value of allogeneic BMT, autologous BMT and intensive chemotherapy during the first complete remission (CR) of acute myelogenous leukemia (AML). An interim analysis of the AML8 EORTC-GIMEMA protocol.Bone marrow transplantationZittoun R, Mandelli F, De Witte T, Willemze R, Tura S
19902189506Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.BloodRodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F
19902188854Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA.European journal of haematologyAvvisati G, Mandelli F, Petti MC, Vegna ML, Spadea A, Liso V, Specchia G, Bernasconi C, Alessandrino EP, Piatti C
19892697401Idarubicin in acute leukaemia. GIMEMA Group.Bone marrow transplantationMandelli F, Annino L, Avvisati G, Giona F, Meloni G, Petti MC, Testi AM, Carella AM, Caronia F, Carotenuto M
19892649141GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. GIMEMA Cooperative Group.British journal of haematology
19892928805Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.Seminars in oncologyPetti MC, Mandelli F
19892653497Prognosis in chronic lymphocytic leukemia (CLL): experience of the Italian cooperative group (GIMEMA).Bone marrow transplantationDe Rossi G
19892653486A randomized comparison of post-consolidation therapy in acute non-lymphoid leukaemia: a study of the Italian cooperative group GIMEMA.Bone marrow transplantationPetti MC, Mandelli F, Vegna ML, Broccia G, Carotenuto M, De Rosa F, Di Marco P, Di Raimondo F, Fioritoni G, Leone G
19892644129High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA.European journal of haematologyPetti MC, Mandelli F, Avvisati G, Covelli A, Amadori S, Liso V, Leone G, De Laurenzi A, Leoni P, Neri A
19873819805Prognosis in chronic lymphocytic leukemia: a retrospective multicentric study from the GIMEMA group.Journal of clinical oncology : official journal of the American Society of Clinical OncologyMandelli F, De Rossi G, Mancini P, Alberti A, Cajozzo A, Grignani F, Leoni P, Liso V, Martelli M, Neri A